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The detailed molecular characterization of lethal
cancers is a prerequisite to understanding resis-
tance to therapy and escape from cancer immunoe-
diting. We performed extensive multi-platform
profiling of multi-regional metastases in autopsies
from 10 patients with therapy-resistant breast can-
cer. The integrated genomic and immune land-
scapes show that metastases propagate and evolve
as communities of clones, reveal their predicted
neo-antigen landscapes, and show that they can
accumulate HLA loss of heterozygosity (LOH). The
data further identify variable tumor microenviron-
ments and reveal, through analyses of T cell recep-
tor repertoires, that adaptive immune responses
appear to co-evolve with the metastatic genomes.
These findings reveal in fine detail the landscapes
of lethal metastatic breast cancer.2690 Cell Reports 27, 2690–2708, May 28, 2019 ª 2019 The Authors
This is an open access article under the CC BY license (http://creativeINTRODUCTION
The genomic characterization of large numbers of primary breast
tumors has revealed significant inter-tumor heterogeneity and
unraveled an increasingly refined molecular taxonomy of early
breast cancer with profound implications for prognostication
and therapeutic stratification (Cancer GenomeAtlas, 2012; Curtis
et al., 2012; Dvinge et al., 2013; Nik-Zainal et al., 2012a, 2012b,
2016). Intra-tumor genomic heterogeneity is also seen in early
breast cancers, highlighting that complex clonal architectures
are already present in primary tumors (Nik-Zainal et al., 2016;
Pereira et al., 2016; Shah et al., 2012; Yates et al., 2015). The
tumor microenvironment (TME) in primary tumors is also different
and distinctive across breast cancer subtypes, in particular with
regards to adaptive immunity (Ali et al., 2016a; Rooney et al.,
2015). The nature of the adaptive immune response, the status
of immunoediting, and the diversity of the T cell receptor (TCR)
repertoire have been analyzed in some early breast cancers
(Munson et al., 2016; Park et al., 2016; Wang et al., 2017), but
such information for metastatic lesions is lacking..
commons.org/licenses/by/4.0/).
Large-scale studies reporting the genomic and transcriptomic
characterization of breast cancer metastasis (Robinson et al.,
2013) and whole-genome sequencing of matched primary tu-
mors and metastases (Yates et al., 2017) have identified targets
that are enriched in metastases compared with primary tumors.
Despite their size, these studies were generally limited to single
metastatic samples.
Genomic evolution is seen in breast cancer metastases
compared with their matched primary tumors. This was first re-
ported in single cases (Shah et al., 2009; Ding et al., 2010). A
couple of warm autopsy case reports have also revealed hetero-
geneity of genomic resistancemechanisms to targeted therapies
across metastases (Juric et al., 2015; Murtaza et al., 2015). More
recently two small autopsy studies with multiple-metastases
profiling have confirmed significant inter-metastasis heteroge-
neity (Hoadley et al., 2016; Savas et al., 2016).
However, a comprehensive molecular analysis of lethal breast
cancers, interrogatingboth themalignant andTMEcompartments
and TCR repertoires, acrossmultiple metastases in several cases
is still lacking. Here we report extensive multi-platform molecular
profiling (DNA sequencing, RNA sequencing, TCR sequencing,
digital pathology of H&E sections, and immunohistochemistry) of
multiple individualmetastases from10warmautopsies of patients
with lethal multi-therapy-resistant breast cancers. This collection
allowed us to characterize the mutational and copy number aber-
ration (CNA) landscapes across the individual metastasis to infer
the clonal ancestries of metastases, assess the TME in each indi-
vidual metastasis, characterize the predicted neo-antigens, and
assess the TCR repertoires across metastases, providing a
detailed molecular characterization of lethal breast cancers that
had been subjected to multiple lines of systemic therapies.
RESULTS
Multi-site Genomic and Transcriptomic Landscapes of
Lethal Metastatic Breast Cancers
We performed warm autopsies in 10 patients with metastatic
breast cancer that had become resistant to multiple lines of ther-
apy (Figure 1A; Figure S1). The cohort is fairly representative of
the major subtypes: 8 were diagnosed with estrogen receptor
(ER)-positive disease, and three of these were HER2-positive;
one was ER-negative and HER2-positive; and one was triple-
negative. In total, 181 samples from multiple metastatic sites in
each patient (mean, 18.5/patient; range, 5–37) were collected
and either fresh-frozen (for DNA and RNA extraction) or
formalin-fixed and paraffin-embedded (FFPE). FFPE samples
from the original breast surgery or diagnostic biopsy were avail-
able from 6 of the patients, and metastatic biopsies during treat-
ment were also collected from 3 patients. The FFPE samples
were used for histological and immunohistochemistry analysis
and for DNA extraction. Plasma samples and a selection of
body fluids, collected during the patient’s life or at autopsy,
were available from all 10 patients (mean, 4.7/patient; range,
1–9/patient) and used for cell-free DNA (cfDNA) extraction.
Comprehensive clinical information for the patients and analyzed
samples can be found in Table S1.
The genomic landscapes of breast cancers are dominated by
CNAs (Ciriello et al., 2013). We used shallow whole-genomesequencing (sWGS) to obtain CNA profiles in 168 samples
from the 10 cases: 122 tumor biopsies (109 metastasis at
autopsy, 4 metastatic biopsies during treatment, 8 primary
breast surgical or diagnostic biopsy specimens from 6 cases,
and a nasopharyngeal olfactory neuroblastoma) and 46 body
fluid samples (24 plasma samples, 5 ascites samples, 9 cerebro-
spinal fluid [CSF] samples, 7 pleural fluid samples, and 1 pericar-
dial fluid sample) (Table S1). For 64 of these metastatic samples
(from 9 of the 10 cases), we also performed RNA sequencing
(RNA-seq). The combined sWGS and RNA-seq data were used
to classify individual metastasis into one of the 10 genome
driver-based subtypes, called integrative clusters (IntClust) (Ali
et al., 2014; Curtis et al., 2012).
The tumor CNA profiles were remarkably similar acrossmetas-
tases in 9 of the 10 cases, and, as expected, all metastases were
classified into the same IntClust (Figure 1B; SI1 in https://doi.org/
10.17632/6cv77bry6m.1). An exception was case 288, an ER-
positive lobular breast cancer, where, besides a 1q gain and
16q lossseen inallmetastases, therewereadditionalandmutually
exclusive CNAs: amplification of 11q13/14, includingCCND1 and
PAK1, in lymph nodes (288-005 and 288-006), the ascites fluid
cell pellet, and ovaries (classified as IntClust2) and 8q and 10q
amplifications in brain and lung and pleura (classified as
IntClust10). Thesedata suggest that allmetastases sharedacom-
monancestorwith 1qgain and16q loss, andearly sub-clonal evo-
lution with remarkable genomic divergence then occurred. The
PAM50 intrinsic subtypes (Parkeret al., 2009)were lessconsistent
across metastases and failed to capture the clade segregation in
case 288 (SI1 in https://doi.org/10.17632/6cv77bry6m.1).
We used whole-exome sequencing (WES) at a median of
1323 depth, including, in each case, DNA extracted from the
buffy coat as the matched germline reference to characterize
the somatic mutational landscape across 79 metastases and 7
body fluid samples, with a range of 2 to 19 metastatic samples
per patient sequenced. We analyzed theWES data with rigorous
filters (STAR Methods) based on a recently described pipeline
(Callari et al., 2017). To further validate the WES mutation calls
(Table S2), we generated ultra-deep targeted sequencing (TS)
(mean depth of 7,57029,8913; mean coverage > 1,0003 for
71%–100% of samples) for amplicons across 464 mutations
(average, 46.4/case; range, 16–127) (Table S3). Matched WES
and TS data were available from 79 samples, and they validated
the robustness of theWES data analysis pipeline we used: sensi-
tivity, 0.85; specificity, 0.99; accuracy, 0.91; precision, 0.99
(STAR Methods).
The WES data identified 15,430 somatic mutations across the
86 samples: 7,809 missense, 1258 truncating, 10 nonstop, 234
in-frame deletions or insertions, and 6,119 other (Table S2).
The mutation burden varied between cases, with a median of
507 mutations per case (range, 113–997), and across metasta-
ses within each case, with a median mutation load of 146 per
metastasis (interquartile range, 86.25). These numbers are
significantly greater (p % 2.2e16, Wilcoxon rank-sum test)
than mutation burdens reported previously for primary breast
tumors within The Cancer Genome Atlas (TCGA), with a median
mutation load of 63.5 (interquartile range, 68).
We classified somatic mutations found in WES as ‘‘metastatic
stem’’ when present in all metastases from the same case,Cell Reports 27, 2690–2708, May 28, 2019 2691
Figure 1. Molecular Profiling of 10 Lethal Metastatic Breast Cancers
(A) Silhouettes representing the 10 patients with number and type of samples profiled using each platform. Patients are grouped as indicated above the
silhouettes according to ER and HER2 status. Samples profiled are labeled according to the color key panel on the right. WES, whole-exome sequencing; sWGS,
shallow whole-genome sequencing; TS, targeted sequencing; RNA-seq, RNA sequencing; RNA-TCRseq, targeted TCR sequencing in RNA; IHC, immunohis-
tochemistry; TNBC, triple-negative breast cancer.
(B) IGV plot showing the copy number aberration (CNA) landscapes across 168 metastases, with samples grouped by patient. The IntClust bar shows
individual sample assignment to one of the 10 integrative clusters (Curtis et al., 2012). Copy number gains and amplifications are indicated in shades of
red; copy number losses are indicated in shades of blue (see bar for corresponding Log ratio). IntClust as per color bar. NC- not classified; ON- olfactory
neuroblastoma.
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Figure 2. Mutational Landscape of 10 Lethal Metastatic Breast Cancers
(A)Mutational burden barplots across 86metastatic samples usingWES.Colors indicatemutations classified asmetastatic stem,metastatic clade, andmetastatic
private.
(B) Oncoprint plot showing the mutations in breast cancer driver genes identified by WES across 84 metastases for the 10 patients.
(legend continued on next page)
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‘‘metastatic clade’’ when present in at least two but not all metas-
tases, and ‘‘metastatic private’’ when present in a single metas-
tasis (Figure 2A). This revealed that the vast majority of the
mutations in individual metastasis were either stem or clade.
We focused our analysis on mutation drivers (Table S4). We
considered a gene a mutation driver (e.g., associated with a
fitness advantage when somatically mutated) using the widely
accepted framework that is based on analyses of large cancer
mutation datasets (Lawrence et al., 2013; Vogelstein et al.,
2013). For our analyses, we defined a list of 109 breast cancer
driver genes identified from reviewing the data in three large
cohorts (Lefebvre et al., 2016; Nik-Zainal et al., 2016; Pereira
et al., 2016) and a list of 527 non-breast cancer drivers (non-over-
lapping) from theCancerGeneCensus (https://cancer.sanger.ac.
uk/census). Mutations were significantly (p = 0.0002, chi-square
test) more common in breast cancer driver genes (58 of 109,
53.21%) than in non-breast cancer driver genes (142 of 527,
26.94%). The total number of driver mutations per metastasis
averaged 11.44 (range, 2–30) (Figure 2B; Figure S2), which is
higher than the estimated number per primary tumor (Martincor-
ena et al., 2017). Metastatic stemdrivermutationswere identified
in all 10 cases: 2 in case288 (CDH1; non-breast driver:CALR), 9 in
case 290 (BUB1B,MAP2K4,MAP3K1,NCOR1, TBX3, and TP53;
non-breastdrivers:ELL,MET, andFLT3), 1 in case291 (ERBB3), 3
in case 308 (ESR1 and PTEN; non-breast driver: NKX2-1), 4 in
case 315 (ATM and GATA3, one missense and one truncating;
non-breast driver: CDC73), 5 in case 323 (CDH1 and PTEN;
non-breast drivers: MET, MYCL, and SDC4), 1 in case DET52
(ATM), 8 in case 328 (FGFR2, NOTCH1, and TP53; non-breast
drivers: AXIN1, CRTC1, LRIG3, SMARCE1, andWHSC1L1), and
5 in case 330 (TP53; non-breast drivers: CARD11, CNTRL,
FBXO11, and PTPRK). A Li-Fraumeni syndrome patient, case
298, had two known metastasized malignancies: HER2-positive
breast cancer and olfactory neuroblastoma. Previously, we
showed that the brain metastasis originated from the breast can-
cer (De Mattos-Arruda et al., 2015). The HER2-amplified brain
metastases had 5 mutation drivers (non-breast drivers:
CACNA1D, DCTN1, FAT1, RAD21, and WHSC1) in addition to
the germline TP53 mutation with associated somatic loss of
heterozygosity. The WES data also revealed that the olfactory
neuroblastoma had anRB1 stemdrivermutation. ThisRB1muta-
tion was detected in one of the two breast cancer brain metasta-
ses (298-009), likely because of contamination by CSF cfDNA.
Indeed, mutations arising from both leptomeningeal neuroblas-
toma and from HER2-positive brain metastases had been de-
tected in CSF cfDNA (De Mattos-Arruda et al., 2015). In case
290, an ovarian tumor sample originally presumed to bemetasta-
tic lacked all 6 breast cancer stem mutations, including a TP53
frameshift mutation. The sample had a different TP53 p.Y220D
missensemutation, and this prompted a pathology review, which
confirmed that it was an independent primary ovarian adenocar-
cinoma. Most cases had also several metastatic clade driver(C) Oncoprint plot showing driver mutations validated by TS (allelic fraction [AF]
(D) Boxplot showing the percentage of stem and clade mutations identified as pr
FFPE blocks from primary surgery samples, except for case DET52, where P1 a
(E) Boxplots of Z score-normalized mutant allele expression from RNA-seq data
transcripts per million. Bars indicate significance of difference (p values < 0.05 a
2694 Cell Reports 27, 2690–2708, May 28, 2019mutations, whereas metastatic private driver mutations were
uncommon.
TS data were also obtained from 40 additional samples for
which only FFPE blocks were available, bringing the total number
of metastatic samples, primary tumors, and liquid biopsies with
TS data to 159 (average per patient, 16 samples; range, 4–25).
The TS validated and extended the WES findings, and this was
particularly informative in case 288, showing that the bilateral
ovarian metastases shared the driver mutations with the lymph
nodes and ascites (Figure 2C; SI2 in https://doi.org/10.17632/
6cv77bry6m.1). In 6 cases, FFPE blocks from the original primary
breast tumor were available, and TS data confirmed that all of
these contained the clonal ancestors of the metastases, but a
percentage of stemmutations and an even larger fraction of clade
mutations were not detected (Figure 2D; SI2 in https://doi.org/10.
17632/6cv77bry6m.1). This included some metastatic stem
driver mutations (case 290, BUB1B absent in two FFPE blocks;
case 308, ESR1 and PTEN absent in the two FFPE blocks;
DET52, ATM not detected in ductal carcinoma in situ (DCIS) or
metastatic axillary lymph nodes) andmostmetastatic clade driver
mutations (SI2 in https://doi.org/10.17632/6cv77bry6m.1).
We next asked whether the expression of the mutant allele
was similar across mutations. A combined analysis of WES
and RNA-seq data were possible in 8 cases (case 291 with a sin-
gle metastasis with combined data and case DET52 without
RNA-seq data were excluded) and revealed that the normalized
expression of the mutant allele was highest in stem, lower in
clade, and lowest in private mutations (Figure 2E).
In summary, metastases keep accumulating mutations,
including mutations in known cancer driver genes, but an
apparent hierarchy of expression (stem-clade-private) of mutant
alleles suggests that, as more mutations accumulate in metasta-
ses, these are increasingly passengers (e.g., not expressed).
A fraction of mutations (including drivers) shared across metas-
tases (stem and clade) were not detectable in the available
primary tumor tissue blocks, suggesting either their origin from
aminor clone in the primary tumor or their acquisition inmetasta-
tic cells that had already left the breast.
Metastases Are Initiated and Maintained as
Communities of Clones
Amonoclonal origin of metastases should result in uniformly high
variant allelic fractions (VAFs) of stem and clade mutations
across all metastases in a case. Plots of allelic fractions of these
mutations across individual metastases revealed a scatter of
allelic fractions using WES data (Figure 3A), and this was vali-
dated using deep TS data. This observation was confirmed by
calculating the cancer cell fraction (CCF), which is the VAF of
each somatic mutation corrected for copy number and purity
estimates, across all of the individual metastases. The probability
distributions of theCCFswere then used to classify each somatic
mutation as clonal or sub-clonal (McGranahan et al., 2015;R 0.1%) for case 288.
esent by TS (AF R 3 SD from AF in matched normal). DNA was extracted from
nd P3 were diagnostic biopsies (breast and axillary lymph node, respectively).
in metastatic stem, metastatic clade, and metastatic private mutations. TPM,
re considered statistically significant).
Figure 3. Breast Cancer Metastases Are Communities of Clones
(A) Pairwise comparisons of raw VAFs fromWES data across 10 pairs of metastases from case 290. Metastatic stem and metastatic clade mutations are colored
as indicated.
(B) Cancer cell fraction (from WES data) of metastatic stem and metastatic clade mutations across metastases in case 290. Each symbol represents a somatic
mutation in an individual metastasis. Probability distributions of the CCFs were used to classify each mutation as either clonal (blue) or subclonal (red). Error bars
represent the 95% confidence interval. Plots for all remainder cases are shown in SI3 in https://doi.org/10.17632/6cv77bry6m.1.
(C) Mean cellular prevalence of mutation clusters identified by PyClone fromWES data across metastases in case 290. Metastatic stem (clusters 6, 9, 10, and 15)
and metastatic clade (clusters 2, 5, 7, 8, 11, 13, and 14) mutation clusters are shown.
(D) Boxplots showing the distribution of mutation AFs in TS data in case 290. Amplicons representative of PyClone exome-derived mutation clusters were
analyzed. Plots for all remainder cases are shown in SI3 in https://doi.org/10.17632/6cv77bry6m.1.
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Figures 3B andS3; https://doi.org/10.17632/6cv77bry6m.1), and
the results were consistent with a fraction of the metastatic stem
and clade mutations being sub-clonal.
We also analyzed the WES data with PyClone (Roth et al.,
2014), a Bayesian clustering method for grouping sets of somatic
mutations and estimating their cellular prevalence (Figure 3C; Fig-
ure S3; SI3 in https://doi.org/10.17632/6cv77bry6m.1). In each
case, a cluster constituted by metastatic stem mutations had
the highest predicted cellular prevalence (mean, 0.94; range,
0.81–0.99) across metastases, as would be expected (288, clus-
ter 2; 290, cluster 6; 308, cluster 1; 315, cluster 3; 323, cluster 2;
328, cluster 4; 330, cluster 5; Det52, cluster 1). However, there
were also stem mutation clusters with lower predicted cellular
prevalence, indicating that these were probably sub-clonal (290:
clusters 9, 10, and 15; 308: clusters 5 and 9; 328: cluster 5; 330:
cluster 6; Det52: cluster 6). Amplicons representative of the clonal
clusters identified from WES were validated using TS, and
this confirmed that a fraction of stem and clade mutations ap-
peared to be sub-clonal (Figure 3D; SI3 in https://doi.org/10.
17632/6cv77bry6m.1).
In summary, these analyses are not compatible with all meta-
static stem and clade mutations being clonal and support the
hypothesis that metastases are initiated and maintained as
groups of cellular clones.
Ancestries of Multiregional Metastases Defined by
Phylogenetic Analyses
We aimed to reconstruct the metastatic seeding patterns with a
series of phylogenetic methods. These included OncoNEM
(Ross and Markowetz, 2016) and Treeomics (Reiter et al.,
2017), which employ nucleotide substitutions and short inser-
tions and deletions (from WES or TS data) as input data; Super-
Freq (Savas et al., 2016), which employs both single-nucleotide
variants (SNVs) and CNAs fromWES as input data; andMEDICC
(Schwarz et al., 2014), which employs CNAs from sWGS and
WES data as input (STAR Methods). Overall, the results were
consistent across these different methods, but for clarity, we
present below the results from OncoNEM (Figure 4; Figure S4A)
using either WES and/or TS data (all other results are provided in
SI4 in https://doi.org/10.17632/6cv77bry6m.1). The OncoNEM
phylogenetic trees of metastases had branched structures in
nine cases (Figure 4; Figure S4A; SI4 in https://doi.org/10.
17632/6cv77bry6m.1). These trees had a limited number of
main branches forming separate clades of distinct but geneti-
cally related, by common ancestry, metastatic samples. The
exception was case 291, where all metastases appeared linearly
related using TS data (Figure S4A; SI4 in https://doi.org/10.
17632/6cv77bry6m.1), but this appearance could be an artifactFigure 4. Phylogenetic Ancestries of Breast Cancer Metastases
(A–D) Phylogenetic trees from the OncoNEM algorithm. Shown are cases 288 (A
metastatic clade mutations are shown. Boxes identify clades. Tree branches are
(E) Phylogenetic tree from the LICHeE algorithm for case 290. Circles represent th
for each cluster. Squares represent each individual metastasis, with colored re
Cross-seeding from the KMT2A clade to 3 metastases (014, 016-A, and 016-B-W
are shown in SI4 in https://doi.org/10.17632/6cv77bry6m.1.
(F) Mutation barplots colored according to mutational signatures for cases 288 a
Case 298: all mutations across samples (left panel) and private mutations of Herresulting from high-quality WES being available from a single
metastasis (291-015). In case 298, there were two breast cancer
metastases analyzed, with the remainder of metastases
sequenced from neuroblastoma, and metastases segregated
by tumor of origin (Figure S4). Case 288 was an ER-positive
lobular cancer with a classical somatic truncating CDH1 muta-
tion (Figure 4A). This patient had bone metastases 10 years after
diagnosis, followed by contralateral axillary lymph node metas-
tases and, later, lung and CNS metastases. The metastases
detected clinically were sampled at autopsy and, in addition,
metastases found at autopsy in both ovaries and the uterus,
and ascites was also collected. The genomic phylogeny was
clear, with two separate clades: one consisting of lymph nodes
(288-005 and -006), ascites (288-022), and bilateral ovarian Kru-
kenberg metastases (13A-0267A10, -A26, and -A27) that were
all ER-positive and had a truncating KMT2C R3868Kfs*13 muta-
tion and 11q13 amplification and a second clade with brain (288-
008), leptomeningeal (CSF pellet, 288-023), and lungmetastases
(288-016, -017, -020, and -021) that were ER-negative, shared
TP53, MAP3K1, and ARID5B mutations, and lacked KMT2C-
R3868Kfs*13 (Figure 4A). Case 290 (Figure 4B), an ER-positive/
HER2 ductal cancer, relapsed with bone metastases 2 years
after diagnosis, followed by liver metastases 13 years later and
death shortly after development of CNS metastases 20 years
after the original diagnosis. At autopsy, several liver metastases
were sampled and carefully mapped, in addition to brain and
stomach metastases being collected. The ovarian sample
collected at autopsy was proven genomically and upon histolog-
ical review to be a separate primary adenocarcinoma (see
above). The genomic phylogeny of the breast cancer metastases
revealed 3 clades. One clade, defined by the presence of an
ESR1 Y537S mutation, in ER-positive metastases (290-014,
-015, -016A, -016B, and -021) mapped to the right inferior lobe
of the liver. A second clade of ER-negative metastases in the
brain (290-005, -007, and -008) and left (290-018 and -019)
and upper right (290-017) lobes of the liver was defined by the
presence of a KMT2A mutation. A third clade was defined by
the absence of both ESR1 and KMT2A mutations in a stomach
metastasis (290-024). Case 308 (Figure 4C), an ER-positive/
HER2 ductal cancer, relapsed with bone metastases 3 years
after surgery, followed 3 years later by lung metastases and
then, in quick succession, CNS and liver metastases and amedi-
astinal mass (formed by pericardial, lung, and rib metastases)
developing in the year prior to death. All 19 metastases analyzed
byWES shared activating ESR1 and truncating PTENmutations.
A genomic clade was defined by a PIK3CA mutation, shared by
pericardial (308-015, -016, and -017) and bonemetastases (308-
018, -019, -020, -021, and -022) forming the mediastinal mass.), 290 (B), 308 (C), and 315 (D). Metastatic stem driver mutations and selected
proportional to the number of mutations.
e mutation clonal clusters and digits within each circle the number of mutations
ctangles representing the cellular prevalence of the respective clonal cluster.
T/muc/IDC) in the ESR1 clade can be seen. Similar plots for all remainder cases
nd 298. Case 288: all mutations (left panel) and clade mutations (right panel).
2+ breast cancer metastases (right panel).
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Most of the remainder of the metastases (except 3 of the menin-
geal metastases: 308-001, -002, and -003) formed a separate
clade defined by a BRCA2 missense mutation. Case 315 (Fig-
ure 4D), an ER-positive/HER2+ ductal cancer treated with neo-
adjuvant chemotherapy and anti-HER2 therapy followed by
surgery, relapsed 3 years after diagnosis with bone and liver
metastases, received multiple lines of therapy mostly targeting
HER2, and within 1 year of death (8 years after diagnosis) had
progressive liver and CNS metastases. At autopsy, all 12 metas-
tases analyzed by WES shared ATM and two different GATA3
mutations. Two genomic clades were identified: one defined by
a truncating mutation in PPP2R1A, comprised of metastases in
the liver (315-001, and -003), peri-pancreatic lymph node (315-
015), para-tracheal lymph nodes (315-007 and -014), and
meninges (315-017 and -018) and a second clade defined by
an ESRRB mutation in liver (315-002, -004, and -005) and lung
(315-009 and -012) metastases. Case 323 (Figure S4A; SI4 in
https://doi.org/10.17632/6cv77bry6m.1), an ER-positive/HER2
lobular cancer, relapsed 2 years after diagnosis with metastases
in bone, pleurae, and lymph nodes. The patient died a year later
with CNS involvement. Genomic phylogeny showed that the two
lymph node metastases formed a single clade with CDH1 and
PTEN stem mutations. Case 328 (Figure S4A), an ER-negative/
HER2+ ductal carcinoma, presented with breast primary and
metastatic disease in the liver, and the patient died 19 months
later. At autopsy, three anatomically distinct brain metastases
were sampled; all shared TP53 and FGFR2mutations and formed
a single clade. Case 330 (Figure S4A), a triple-negative ductal
cancer, was originally treated with neo-adjuvant chemotherapy,
with pathological complete response at surgery. The patient
relapsed after 12 months with CNSmetastases, followedmonths
later by breast metastases. Phylogenetic analysis revealed two
clades: breast metastases (330-001 and -002) with GPS2,
MSH2, and FSIP2 mutations and brain (330-005) and meningeal
(330-003 and -004) metastases with AR and MLLT4 mutations.
Case DET52 (Figure S4A), an ER-positive/HER2+ ductal carci-
noma, presented with widespread metastatic disease and had
a tree rooted in a single brain metastasis resected surgically
18 months prior to death (Det52, mt4), with a clade formed
by ovary (Det52, mt7), liver (Det52, mt5), and lung (Det52, mt6)
metastases. The OncoNEM tree constructed from TS data (SI4
in https://doi.org/10.17632/6cv77bry6m.1) showed one clade
formed by diagnostic DCIS and axillary lymph node (Det52,
mt2) biopsies and invasive breast cancer sampled at autopsy
(Det52, mt3), and another clade formed by the distal metastases
collected at autopsy (bone, mt8; liver, mt5; ovary, mt7) and the
surgically resected brain metastasis (mt4).
Because metastases were grouped in clades, we asked
whether cross-seeding occurred both within and between
clades. TS data revealed individual instances of cross-seeding
(Table S3; SI2 in https://doi.org/10.17632/6cv77bry6m.1), and
therefore we used a systematic approach to quantify these.
Cross-seeding is the result of a clone (or a group of clones)
from one metastasis recirculating and seeding another metas-
tasis at a different site. We used the PyClone mutation clusters
(see above) as a surrogate of metastatic cellular clones and
entered these into the LICHeE phylogenetic tool (Popic et al.,
2015), which orders clones across samples by comparing their2698 Cell Reports 27, 2690–2708, May 28, 2019cellular prevalence. This revealed that cross-seeding between
clades occurs in a particular pattern: a common seeder for one
clade can cross-seed metastases belonging to a separate clade
(Figure 4E; SI4 in https://doi.org/10.17632/6cv77bry6m.1).
Cross-seeding within a clade was rare.
In summary, the genomic phylogenies of metastases are com-
plex but consistently show that, within a patient, individual
metastasis can be grouped in phylogenic clades that share a
common genomic ancestry, and this ancestry is mutually exclu-
sive with the genomic ancestries of other clades. Each clade
group of metastases is therefore likely seeded by a common
ancestor, but cross-seeding between metastases can happen,
although it appears that this occurs to a rather limited degree
and mostly between clades.
Mutational Signatures across Metastases
Mutational signatures, generated by different mutational pro-
cesses, areengraved in thegenomesofbreastcancers (Nik-Zainal
et al., 2016). Toextract these signatures accurately, direct applica-
tion of non-negative matrix factorization (NNMF) on our 86 WES
samples would lack power; hence, data from 240 additional
WES single metastatic breast samples (Lefebvre et al., 2016)
were included in the analysis. To identify canonical signatures,
the rank and number that could be extracted by NNMF were
allowed to vary, and fourwere robustly seen: the APOBEC-related
signatures 2 and 13 (cosine similarity of 0.98 and 0.96, respec-
tively); signature 17, comprising mostly T > G mutations (cosine
similarity of 0.95); and signature 1, associated with demethylation
of cytosines (cosine similarity of 0.91) (Figure 4F; Figure S4B).
We explored whether signatures stratified across stem, clade,
and private mutations. In case 288, considering all mutations re-
vealed signatures 1, 2, and 13 in all metastases and signature
17 only in ER-negative metastases, whereas considering clade
mutations revealed that signature13wasexclusiveof ER-positive
metastases (Figure 4F, top panels). In case 298, signatures 2 and
13 were seen only in Her2+ breast cancer brain metastases, with
enrichment of signature13 inprivatemutations (Figure 4F, bottom
panels). In case 328, signature 17was seen across all 3 brainme-
tastases but restricted to private mutations in only two (SI4 in
https://doi.org/10.17632/6cv77bry6m.1), suggesting enrichment
with later tumorevolution. In caseDET52, a single lungmetastasis
(DET52-mt6)with signature 17 (Figure S4B) carried in that context
the ERBB4 mutation, believed to be the driver of resistance to
lapatinib, which ultimately killed the patient.
The assignment of mutations to the four canonical signatures
revealed a considerable number of ‘‘residual’’ mutations (SI4 in
https://doi.org/10.17632/6cv77bry6m.1). Mathematically small
fluctuations in either direction of these residual mutations may
reflect the lack of power in WES data. However, a consistent
excess of positive residuals indicates that many mutations may
be due to mutational processes previously unaccounted for.
To exclude the possibility that these residual mutations arise
simply because of fitting to fewer canonical signatures than truly
present, the dataset was fitted to the 12 breast cancer-associ-
ated signatures and all 30 canonical signatures in the Catalogue
of Somatic Mutations in Cancer (COSMIC). This revealed
improvement in overall fitting (as expected) at the expense of
increasing negative residuals (p = 4e–16, Wilcoxon signed-rank
Figure 5. Neo-antigen Landscape across Breast Cancer Metastases
(A) Bar plots of the neo-antigen landscape across cases (top panel) and LOH at the HLA allelic locus across metastases (bottom panel).
(B) Violin plots of observed/expected neoantigen ratios across individual metastases. For each metastasis, 100 replicate expected mutation simulations were
used, and each violin plot shows the distribution of the log2-transformed ratio. The ratio represents the relative deviation of the neo-epitope rate from expectation.test), suggesting mis-assignment to signatures that are unlikely
to be present. Next, to demonstrate that the excess of residuals
was not simply due to using WES data, the same analysis was
done in 640 WES primary cancers (SI4 in https://doi.org/10.
17632/6cv77bry6m.1). Comparison of residuals (root-mean-
square error [RMSE]) between primary and metastatic samples
revealed that the fitting was much worse for metastatic cancers
(p < 2.2e16, Wilcoxon rank-sum test). Hence, we hypothesize
that metastases with a longer history of exposure to mutational
processes may carry additional signatures that are detected as
the excess residuals. Indeed, cosine similarities between muta-
tional profiles of metastatic samples and primary samples (with
additional bootstrapping performed 10,0003; median p =
3e4) revealed greater interpatient similarity in primary versus
metastatic cancers. To further support this finding, we used
the Shannon entropy index to quantify the diversity within the
normalized mutational profile (considering the 96 permutations
of triplet mutation context) of each sample and found greaterdiversity within metastatic samples compared with primary sam-
ples (Wilcoxon rank-sum test, p = 1.6e16). Moreover, the evo-
lution of diversity through the phylogenetic trees revealed a
greater Shannon entropy index when all mutations were consid-
ered (Wilcoxon signed-rank test, p = 1e14) versus stem muta-
tions (SI4 in https://doi.org/10.17632/6cv77bry6m.1).
In summary, although metastases carry the same mutational
signatures described in primary breast cancers, the increased
residuals observed suggest that they probably carry additional
mutation patterns. Remarkably mutation signatures are either
shared across all metastases or across metastases within a
clade, suggesting that they are scars of mutational processes
operative in the metastatic founder clones.
The Predicted Neo-antigen Landscape across
Metastases
Neo-antigens encoded by tumor-mutated genes result in neo-
peptides that can be presented by the major histocompatibilityCell Reports 27, 2690–2708, May 28, 2019 2699
class I complex. These neo-peptideshave thepotential for binding
TCRs and eliciting anti-tumor adaptive immune responses (Brown
et al., 2014). We integrated WES and RNA-seq data to predict in
silicoputative neo-antigens (STARMethods). Across themetasta-
ses, around 16% of expressed non-silent metastatic mutations
yielded 1 or more predicted neo-epitopes (with IC50 < 500 nM),
but only a small fraction (3%) of predicted neo-antigens originated
from cancer drivers. Most predicted neo-antigens arise from
metastatic stem (56%) and metastatic clade mutations (36%)
(Figure 5A, top panel). Recently it was reported that loss of hetero-
zygosity (LOH) at theHLA locusoccursasamechanismof immune
escape (McGranahan et al., 2017). Using the same method, we
identified clonal LOH (present in every single metastasis) in cases
330 (in all three HLA class I alleles) and 315 (in HLA-C) and subclo-
nal LOH (present in a fraction of themetastases) in cases 288, 290,
298, and 308 (Figure 5A, bottom panel). In case 330, the neo-anti-
gens were significantly (p = 0.01, Wilcoxon rank-sum test) more
commonly predicted to be presented by the lost HLA alleles. In
the remainder of cases, this difference was not significant for any
of the lost HLA alleles. Nevertheless, on average, 55.4% of pre-
dicted neo-antigens associated with the lost HLA allele and,
hence, could not be presented directly by tumor cells.
We next asked, using a previously reported approach (Rooney
et al., 2015), whether there was evidence for selected elimination
of immunogenic sub-clones across individual metastases. The
method relies on determining the ratio of observed-to-expected
neo-epitopes, and to estimate the distribution of the number of
expected neo-epitopes, we used simulated mutations that
mimic the observed mutations (STAR Methods). We generated
100 datasets of simulated mutations for each sample and
calculated the corresponding observed-to-expected ratios
both for individual metastases and after combining all metasta-
ses from the same case or from the same organ across cases.
The results (Figure 5B) showed that only one single metastasis
(328-003, brain metastasis) had all 100 ratios below one (i.e.,
empirical p z 0.01), suggesting immunoediting. We also
estimated a null distribution for the mean observed-to-expected
ratio using 20 of the simulated mutation datasets, generating
for each one of them 100 simulated datasets and calcu-
lating the mean of the ratios (SI5 in https://doi.org/10.17632/
6cv77bry6m.1). When grouping all metastases per case, none
had a mean ratio lower than expected (compared with the 20
replicates) (Figure S5A), and when lumpingmetastases by target
organ across cases, no organ site showed a trend suggesting
immunoediting (Figure S5B).
In summary, in disseminated lethal breast cancer, most of the
predicted neo-antigens originate from mutations shared across
metastases, with only a small number being private to individual
metastasis. LOH of HLA alleles was observed in many metasta-
ses (clonal in two cases), and non-synonymous mutations pre-
dicted to be neo-antigenic were frequently associated with the
lost HLA allele, suggesting tumor cell immune escape. Overall,
the number of predicted neo-antigens in each metastasis was
only exceptionally lower than expected, suggesting that, in late
metastatic breast cancer, tumor cells are already in the escape
phase of the immunoediting process, where cancer cells have
acquired the ability to circumvent immune recognition or
destruction (Schreiber et al., 2011).2700 Cell Reports 27, 2690–2708, May 28, 2019Heterogeneity of the TME across Metastases
We characterized the TME across individual metastases using a
combination of computational pathology of digitally scanned
H&E slides (64 frozen sections of the tissue used for RNA extrac-
tion and 102 FFPE tumor biopsies), manually scored immunohis-
tochemistry (IHC) of a set of immunemarkers (n = 102), and gene
expression data (RNA-seq, n = 64).
We previously reported the use of digitized H&E slides and
machine learningmethods to classify cells within a tumor as can-
cer, stromal, or lymphocytes (Ali et al., 2016b). Using this
approach, we analyzed 166 frozen and paraffin-embedded met-
astatic and primary tissue sections (STAR Methods), and the
data revealed significant heterogeneity of cell numbers, frac-
tions, and densities across individual metastases, showing the
variable spatial architecture of the TME (Figures 6A and S6A;
SI6 in https://doi.org/10.17632/6cv77bry6m.1). In parallel IHC
(102 FFPE sections), semiquantitative analysis by expert pathol-
ogists revealed variable numbers of CD4 and CD8 T cells per
surface area (Figure 6A, bottom panel).
The patterns of immune infiltration can also be inferred using
deconvolution of bulk gene expression (Hackl et al., 2016). In pri-
mary tumors, these patterns are variable across subtypes and
associated with response to therapy and survival (Ali et al.,
2016a). We performed these analyses across metastases from
9 caseswith available RNA-seq data. The immune cytolytic activ-
ity score (Rooney et al., 2015) was highly variable across metas-
tases (Figure 6B). We further characterized TME expression
signatures using a recently reported deconvolution methodology
(Charoentong et al., 2017). This tool provides normalized
Z scores for a list of cancer immunity parameters, including 20
single factors (major histocompatibility complex [MHC] mole-
cules, immunoinhibitors, and immunostimulators) and six cell
types (STAR Methods). These Z scores were visualized as
immunophenograms for each individual metastasis or used to
generate clustered heatmaps across metastases for each case.
Inspection of the immunophenograms revealed variability of the
TME in metastases both between and within each of the cases
(Figure 6C; SI6 in https://doi.org/10.17632/6cv77bry6m.1). This
was mirrored in IHC analysis of a total of 14 TME markers, which
also revealed heterogeneous TME across metastases (SI6 in
https://doi.org/10.17632/6cv77bry6m.1). Unsupervised hierar-
chical clustering based on the Euclidean distance matrix of the
Z scores across metastases showed that the immune parame-
ters tended to cluster naturally into major functional groups:
immunogenic or immune-suppressive (Figure 6D; Figure S6B).
The clustering of the individual metastasis in each case also
had interesting features. In cases 288, 290, and 330, it appeared
as if the TME clustering of themetastasesmirrored their genomic
clades (Figure 6D; Figure S6B). The TME clustering seen could
simply reflect the metastatic organ site, but in other cases,
metastases to the same organ had very distinct TMEs:meningeal
and bone metastases in case 308, liver metastases in case 315,
and brain metastases in case 328 (Figure S6). We also examined
the expression of immunomodulators (Tang et al., 2018; Thors-
son et al., 2018), and this also revealedmetastases largely segre-
gated by target organ and by genomic clade (Figure 6E).
In summary, multiple orthogonal methods congruently





Figure 6. The Tumor Microenvironment Is Heterogeneous across Metastases
(A) Median lymphocyte density (computational pathology of digitally scanned H&E slides) (top panel) and CD4 and CD8 T number per square millimeter (IHC
staining) (bottom panel).
(B) Cytolytic activity score across metastases based on transcript levels of granzyme A (GZMA) and perforin (PRF1).
(C) Immunophenograms across metastases of case 288. Each immunophenogram is color-coded in the outer part of the wheel (red, positive Z score; blue,
negative Z score) for each of the parameters and gray-scaled in the inner part of the wheel, with a weighted averaged Z score within the respective category.
Z scales are shown in the bars. MHC, antigen processing; CP, checkpoints/immunomodulators; EC, effector cells; SC, suppressor cells.
(D) Heatmaps depicting two-way unsupervised hierarchical clustering of immune parameters and metastases for patients 288 and 330.
(E) Gene expression of immunomodulators from RNA-seq gene expression (76 genes from Thorsson et al., 2018). Z-scored transformed TPMs are plotted across
all 64 RNA-seq metastases from 9 patients.
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Figure 7. Analysis of the TCR Repertoire across Metastases
(A) Boxplots of proportions of TCR reads classified as metastatic stem, metastatic clade, and metastatic private. Bars indicate significance of differences (not
significant [NS], p > 0.05; ***p < 0.0005).
(B) Boxplots of overlap coefficients between metastatic sites of TCR b chain nucleotide sequence repertoires. Data for case 308 is shown.
(C) Boxplots showing the TCR clone sizes according to their stem, clade, or private status. *p < 0.05.
(D) Clustering of TCR b chain CDR3 amino acid sequences using Jaccard distance across metastases.
(E) Jaccard tree for the TCR b chain CDR3 amino acid sequence (top panel) and the WES phylogenetic tree from OncoNEM (bottom panel) for case 308.
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metastatic sites within a patient, although it can be both relatively
homogeneous in metastatic clades in some cases and different
across metastases to a particular organ in other cases.
The Repertoire of TCRs across Metastatic Sites
The landscape of neo-antigens is thought to determine the
immunogenicity of cancers and, in particular, the anti-tumor re-
sponses mediated by T cells. We therefore characterized the
repertoires of TCRs in tumor-infiltrating lymphocytes (TILs)
across metastases and integrated this with the genomic data
(Figure 7; Figure S7).
We sequenced the antigen binding regions of TCRs of TILs us-
ing direct amplification of the a and b TCR chains in RNA isolated
from 70 metastases from 8 patients (STAR Methods). Each RNA
sample was amplified and high-throughput-sequenced sepa-
rately for a and b TCR chains. These sequences represented a
diverse set of TCRs with a mean of 5,204 unique TCR sequences
per sample (a, 5,551; b, 4,857). The a and b chain V-J gene usages
were highly correlated in each metastatic sample and across all
metastases, attesting to the quality of the data (Figure S7A).
Public TCRs are defined as TCRs that are shared between un-
related individuals, and these are thought to bind shared pep-
tides; for example, of viral origin (Li et al., 2012). Therefore, we
focused our analyses on non-public TCRs by first removing
both the TCR b chain sequences derived from unrelated individ-
uals in the Adaptive database (Dean et al., 2015) and the TCR a
and b chain sequences shared between any of the 8 cases pro-
filed. This filtering step enriched for TCRs that bind patient-
specific antigens, including tumor neo-antigens (Figure S7B).
The non-public TIL TCRs were classified in each case as stem
when shared between all metastatic sites in a patient, clade
when shared between some sites, or private when found in a
single metastasis. Interestingly, a significant fraction of the
TCR repertoire was comprised of stem (mean a/b, 21.60%/
24.53%) and clade (mean a/b, 58.13%/49.67%) clonotypes (Fig-
ure 7A). These data indicate that a significant proportion of T cell
clones in TILs from an individual metastasis either recirculate
to other metastatic sites or that T cell clones recognizing the
same neo-antigen are recruited to several metastatic sites
independently. Given the evidence for T cell sharing across indi-
vidual metastases, we quantified the degree of clonal sharing
(STARMethods) of CDR3 a and b clonotypes acrossmetastases
and showed significant variation between sites and patients.
This is exemplified by case 308, which revealed significant differ-
ences in TCR clonal sharing between and within metastatic
target organs (Figure 7B) (see SI7 in https://doi.org/10.17632/
6cv77bry6m.1 for the remainder of cases). Indeed, the TCR
clonal overlap coefficient was significantly higher between me-
tastases within the same target organ than in metastases to
different target organs. In addition, there was a high TCR clonal
overlap coefficient between bone and pericardium metastases,
which formed a mediastinal mass in case 308.
We next assessed the clonal architecture of tumor-infiltrating
T cells at each site using sequence diversity measures (Bash-
ford-Rogers et al., 2013; Madi et al., 2017). This measures the
unevenness of TCR clone sizes (clonality) within each site,
where each TCR clone is defined by a unique TCR sequence,
and its size is defined by the frequency of that sequence withinthe total repertoire (STAR Methods). The T cell clonality in total
mononuclear cells, CD3+ T cells, naive T cells, and central
memory T cells from a healthy individual’s blood sample, pro-
filed using the same method, were very distinct from breast
cancer metastases T cells; although the former exhibited only
low levels of expanded T cell clones with mean largest cluster
sizes of 3.93% (range, 1.03%–7.01%), most metastases
showed higher levels of specific T cell clonal expansion (mean
largest cluster size, 14.97) (Figure S7C). Interestingly stem
and clade TCR clones were significantly more expanded than
TCR clones from a single metastasis (Figure 7C; SI7 in https://
doi.org/10.17632/6cv77bry6m.1), and the shared TCR clones
showed significant differences in clonal representation be-
tween metastatic sites, contrasting with relatively uniform
clones in normal samples (Figure S7D; SI7 in https://doi.org/
10.17632/6cv77bry6m.1). The fact that T cell clones that are
shared are also significantly enlarged compared with site-spe-
cific clones is suggestive of immune surveillance between
metastases.
Clustering of TCR repertoires of TILs by the level of sharing of
CDR3 amino acid sequences (using the Jaccard index) revealed
that TCR repertoires were distinct between each metastatic
breast cancer patient (Figure 7D). There was only a small degree
of sharing of TCR CDR3 sequences between unrelated patients,
which may occur by chance at low frequencies, and high levels
of TCR CDR3 sequence sharing between metastases within
each patient. Indeed, within each patient, the unsupervised
CDR3 TCR clustering nearly accurately segregated the metasta-
ses by organ, and clustering was consistent with both a and b
TCR chains (SI7 in https://doi.org/10.17632/6cv77bry6m.1).
Using two methods for evaluating hierarchical tree structure,
cophenetic correlation and Robinson-Foulds metric (STAR
Methods), we showed that the TCR repertoires clustered signif-
icantly by organ (p < 2.2e16) rather than by chance or by differ-
ences in TCR repertoire sampling depth.
We noted that, in 4 of the autopsy cases (288, 290, 308, and
315) where both WES and RNA TCR sequencing data were
available across several metastases, the tumor OncoNEM
phylogenetic trees and the TCR Jaccard phylogenetic trees
had remarkably similar structures (Figure 7E; SI7 in https://doi.
org/10.17632/6cv77bry6m.1). To formally test this, we used
the cophenetic statistic to assess the correlation. This analysis
confirmed that, in 3 of the 4 cases (288, 315, and 308), the
TCR a chain trees significantly correlated with the genomic trees
(cophenetic correlation of 0.460, 0.235 and 0.518; p% 0.05), and
in 2 of the 4 cases (288 and 308), the TCR b chain trees also
correlated with the genomic trees (cophenetic correlation of
0.38 and 0.598, p% 0.08 [borderline] and p < 0.01, respectively)
(Figure 7E; SI7 in https://doi.org/10.17632/6cv77bry6m.1).
To further corroborate the robustness of the findings, the cor-
relation between the RNA-seq and the TCR repertoire datasets
(STAR Methods; Figure S7E) was tested. The sum of the log10
transcripts per million (TPM) values for the four CD3 complex
genes (a unique marker for all T cells) and the number of TCR
reads (the sum of a and b chains) were highly statistically corre-
lated (Pearson correlation, 0.717; p < 1.684e10).
In summary, these data provide a detailed view of the adaptive
immune response in metastatic cancer and reveal that the TCRCell Reports 27, 2690–2708, May 28, 2019 2703
repertoire of TILs is highly diverse between cases; within each
case, a significant fraction of TIL TCRs are shared between me-
tastases, suggesting immune surveillance between metastatic
sites. The clonal prevalence of shared TIL TCRs in each individ-
ual metastasis can be very different; the TCR repertoire clusters
metastases by target organ within each case, and tumor phylo-
genetic trees appear to be correlated with TIL-TCR trees across
metastases within a case. This correlation suggests co-evolution
between tumor diversity and T cell response across metastases.
DISCUSSION
The comprehensive molecular analysis of multi-regional metas-
tases collected from 10 autopsies of breast cancer patients
subjected to multiple lines of therapy described here details
the heterogeneous landscape of genomic aberrations, TME fea-
tures, and T cell adaptive immune responses in lethal cancer.
The only comparably sized study (10 autopsy cases) was
recently published, but it limited its analysis to DNA sequencing
of the available 41 paraffin-embedded tumor samples (Brown
et al., 2017).
The genomic landscapes revealed that metastatic private
driver mutations are relatively uncommon and that nearly all
driver CNAs and SNVs are shared across all (stem) or a subset
(clade) of the metastases. The normalized expression of the
mutant allele is progressively lower in metastatic clade and met-
astatic private mutations compared with metastatic stem muta-
tions, suggesting that, as metastases evolve from common
ancestors, they accumulate higher proportions of mutant alleles
that are passengers and, therefore, have lower or suppressed
expression.
In 6 cases, targeted deep sequencing of available primary
samples confirmed that a fraction of tested mutations were de-
tected at high CCFs, confirming that the metastases originated
from the surgically resected tumor. However, in five of these,
deep sequencing failed to identify some metastatic stem muta-
tions and most of the metastatic clade mutations tested,
including cancer driver mutations. Given the high depth and
quality of the TS data, it is exceedingly unlikely that a trivial tech-
nical issue (allele dropout) could explain this result. The most
likely scenarios are either that metastases originate from aminor
clone not sampled in the primary tumor because of spatial het-
erogeneity or that metastatic stem and clade mutations could
be acquired by metastatic cancer cells after these leave the
breast. Indeed, in case Det52, we reported previously that
metastatic stem mutations could be identified as a minor clone
in the axillary lymph node, consistent with an original metastatic
ancestor being present at that site (Murtaza et al., 2015).
Whether that is the rule or whether other sites (e.g., the bone
marrow) (Harper et al., 2016; Hosseini et al., 2016) could have
a similar metastases seeder role will require studying larger
numbers of cases.
The genomic phylogenetic analysis showed clearly that the
multiple metastases in each case (with one exception) grouped
into a small number of clades (up to three). These clades were
populated by a common seeder, itself a descendant of the
original metastatic ancestor, and clades were anatomically
distributed to one or more target organs. In each individual2704 Cell Reports 27, 2690–2708, May 28, 2019metastasis within a clade, the mutations were either shared
with other clade members or private, and this suggests that
seeding occurs most likely in a single spreading event. Further-
more, the genomic segregation of the metastases was nearly
complete, and only a limited amount of cross-seeding between
clades was observed. Cross-seeding within a clade was rare.
These data suggest that metastatic spread occurs as a result
of a limited number of seeding events.
The classical view of the metastatic cascade has focused on
seeding from single cells (Lambert et al., 2017). However, circu-
lating tumor cell (CTC) clusters occur in the blood of patients with
metastatic breast cancer, and mouse models show that CTC
clusters are oligoclonal and, although rare compared with single
CTCs, have 23- to 50-fold increased metastatic potential (Aceto
et al., 2014). Our analysis using PyClone and CCF is consistent
with metastases often being composed of communities of
genomic clones, as indicated by metastatic stem mutations
and metastatic clade mutations frequently being sub-clonal.
Our previously published data regarding primary tumors (Shah
et al., 2012) and patient-derived tumor xenografts (Bruna et al.,
2016; Eirew et al., 2015) also appear to show that cancers are
communities of genomic clones. The polyclonal origin of breast
cancer metastases has also been reported by others (Hoadley
et al., 2016) and has profound implications for the study of met-
astatic biology and for devising therapeutic strategies.
The mutation signatures across the metastases are a reflec-
tion of the mutational processes operative during the life history
of the cancer. We identified previously reported mutational sig-
natures in all cases and evidence of residual mutations not
explained by any of the canonical mutation signatures described
to date (which have been almost exclusively derived from pri-
mary cancers). Larger autopsy series and WGS data will be
required to definitively establish whether metastases can accu-
mulate novel mutation signatures reflecting both their longer
natural history and the combined scars of therapies and the
effects of immunoediting.
The 10 cases analyzed were patients subject to multiple lines
of targeted therapy (hormone therapy and anti-Her2) and
chemotherapy, to which each patient had developed resistance.
The small cohort and the diversity of cancer treatments the pa-
tients received do not allow confident identification of the mech-
anisms of resistance. Nevertheless, case 308 had a canonical
activating mutation of ESR1 (Robinson et al., 2013; Toy et al.,
2013) across all metastases, and this mutation, a likely mecha-
nism of resistance to hormone therapy, would have been identi-
fied with a single metastatic biopsy. This contrasts with cases
where two different mechanisms for hormone therapy resistance
were identified: losing ER expression in some metastases and
11q13 amplification in ER-positive metastases in case 288 and
losing ER expression in some metastases and an activating
ESR1 mutation in ER-positive metastases in case 290. These
distinct forms of resistance in both cases correspond to their
metastatic phylogenetic clades and imply that for both to be
identified would require at least two metastatic biopsies.
The combined analysis of somatic cancer aberrations, TME
deconvolution, predicted tumor neo-antigens, and TCR reper-
toire from lethal metastatic breast cancer autopsies afforded
us a unique opportunity to analyze the interactions between
themalignant and TME compartments acrossmulti-regional me-
tastases. Most of the predicted neo-antigens arose from meta-
static stem and clade mutations, and this result concurs with
what has been reported in lung cancer (McGranahan et al.,
2016). Immune selection, as evidenced by depletion of neo-epi-
topes, was scarcely seen across metastases, suggesting that in
advanced breast cancer, most of the metastases are in the
escape phase of immunoediting (Schreiber et al., 2011).
TME composition and its spatial architecture were also het-
erogeneous across metastases from individual cases. This
TME diversity had no direct correlation with evidence for differ-
ential immunoediting and has also profound implications for
immune checkpoint inhibitor therapy because, for example,
PD1 and PDL1 expression was different across metastases.
The occurrence of HLA LOH suggests that tumor cells also
evolve to avoid presenting neo-antigens, and this might also
contribute to immune escape.
A major determinant of the ability of the adaptive immune sys-
tem to eliminate tumors is the diversity of the TCR repertoire in
TILs. Although the level of sharing of TCRs between patients
was minimal, an important observation was the large fraction of
TCRs either shared across all the metastases (stem TCRs) or in
at least 2metastases (clade TCRs) within a case. This finding sug-
gests that specific TCRs reacting to tumor neo-antigens, which
are mostly stem and clade, are present across metastatic sites.
Shared TCRs could be clonally dominant in an individual metas-
tasis and minor clones at other metastatic sites. We could not
identify any correlation between clonal inequality (measured by
either Gini or Shannon index) or intra-tumor heterogeneity, muta-
tion, or neo-antigen burden (data not shown); however, other
factors, such as chemokines, may influence the migration and
proliferation of T cell clones between sites.
TCR similarity was higher in metastases within a given meta-
static organ. This observation led us to cluster the metastases
across all patients and organs based on TCR diversity and/or
similarity, revealing each patient clustered separately from all
others and, within an individual patient, nearly perfect metastatic
organ segregation. Very distinct TCR repertoires between pa-
tients were an expected result. However, within an individual
patient, TCR repertoires in metastases to the same organ were
more similar. This observation was robust and highly statistically
significant, suggesting that TCR repertoires in TILs are tuned to
target organs where metastases tend to share a common
genomic ancestor. Indeed, genomic phylogenetic trees and
TCR repertoire Jaccard trees showed remarkably similar archi-
tectures in the 4 cases where we had parallel WES and TCR
sequencing data from more than 4 metastases. We tested this
more formally using tools developed by ecologists, and the
correlation was statistically significant in 3 of the cases. This is
suggestive of co-evolution of cancer genomes and the TCR rep-
ertoires of the samemetastases, providing unique patient-based
evidence for the cancer immunoediting hypothesis. An alterna-
tive explanation that is not contradictory is that tissue-resident
T cells, which have tissue-specific TCR repertoires, infiltrate
metastases, giving rise to the observed TCR similarities. Such
differences in the composition of TCR repertoires between tis-
sues can be part of the forces that influence clonal evolution of
metastatic cancer cells. These findings can have importantimplications for T cell-based immunotherapies. For example,
peptides that are derived from neo-antigens and are used for
vaccination should be tailored differently for different metastatic
sites. Similarly, adoptive T cell therapies based on patient T cells
or engineered receptors should also take into account differ-
ences in TCR composition and reactivity between metastatic
sites. On the other hand, the presence of TCRs shared across
metastases and the fact that most neo-antigens are also shared
across all or subsets of metastases could be translated into
either T cell-based therapies or modulation of immune check-
points that would elicit an effective anti-tumor response across
all metastases.
The extensive profiling of multi-regional metastases in lethal
breast cancers resistant to several lines of therapy analyzed
here has provided a unique glimpse into how metastases prop-
agate and evolve, how drug resistance mechanisms vary, how
their predicted neo-antigen landscapes look, how they shape
and/or are shaped by the TME, and how the T cell adaptive
immune response appears to co-evolve with the metastatic ge-
nomes. These data should motivate the research community to
consider launching a lethal cancer genome project. This project,
across common human cancers in a sufficiently large number of
autopsy cases from patients with detailed therapy exposure
histories, will produce the detailed integrated maps required
for understanding resistance to therapy and escape from cancer
immunoediting.
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Bouchard-Côté, A., and Shah, S.P. (2014). PyClone: statistical inference of
clonal population structure in cancer. Nat. Methods 11, 396–398.
Saunders, C.T., Wong, W.S., Swamy, S., Becq, J., Murray, L.J., and Chee-
tham, R.K. (2012). Strelka: accurate somatic small-variant calling from
sequenced tumor-normal sample pairs. Bioinformatics 28, 1811–1817.
Savas, P., Teo, Z.L., Lefevre, C., Flensburg, C., Caramia, F., Alsop, K., Man-
sour, M., Francis, P.A., Thorne, H.A., Silva, M.J., et al. (2016). The Subclonal
Architecture ofMetastatic Breast Cancer: Results from a Prospective Commu-
nity-Based Rapid Autopsy Program ‘‘CASCADE’’. PLoS Med. 13, e1002204.
Scheinin, I., Sie, D., Bengtsson, H., van de Wiel, M.A., Olshen, A.B., van Thuijl,
H.F., van Essen, H.F., Eijk, P.P., Rustenburg, F., Meijer, G.A., et al. (2014). DNA
copy number analysis of fresh and formalin-fixed specimens by shallow
whole-genome sequencing with identification and exclusion of problematic re-
gions in the genome assembly. Genome Res. 24, 2022–2032.
Schreiber, R.D., Old, L.J., and Smyth, M.J. (2011). Cancer immunoediting:
integrating immunity’s roles in cancer suppression and promotion. Science
331, 1565–1570.
Schwarz, R.F., Trinh, A., Sipos, B., Brenton, J.D., Goldman, N., and Marko-
wetz, F. (2014). Phylogenetic quantification of intra-tumour heterogeneity.
PLoS Comput. Biol. 10, e1003535.
Shah, S.P., Morin, R.D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., Dela-
ney, A., Gelmon, K., Guliany, R., Senz, J., et al. (2009). Mutational evolution
in a lobular breast tumour profiled at single nucleotide resolution. Nature
461, 809–813.
Shah, S.P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding,
J., Tse, K., Haffari, G., et al. (2012). The clonal and mutational evolution spec-
trum of primary triple-negative breast cancers. Nature 486, 395–399.
Shen, Z., Qu, W., Wang, W., Lu, Y., Wu, Y., Li, Z., Hang, X., Wang, X., Zhao, D.,
and Zhang, C. (2010). MPprimer: a program for reliable multiplex PCR primer
design. BMC Bioinformatics 11, 143.
Shukla, S.A., Rooney, M.S., Rajasagi, M., Tiao, G., Dixon, P.M., Lawrence,
M.S., Stevens, J., Lane, W.J., Dellagatta, J.L., Steelman, S., et al. (2015).
Comprehensive analysis of cancer-associated somatic mutations in class I
HLA genes. Nat. Biotechnol. 33, 1152–1158.
Soetaert, K., Van den Meersche, K., and van Oevelen, D. (2009). limSolve:
Solving Linear Inverse Models, R-package version 1.5.1.
Stamatakis, A. (2014). RAxML version 8: a tool for phylogenetic analysis and
post-analysis of large phylogenies. Bioinformatics 30, 1312–1313.2708 Cell Reports 27, 2690–2708, May 28, 2019Tang, J., Shalabi, A., and Hubbard-Lucey, V.M. (2018). Comprehensive anal-
ysis of the clinical immuno-oncology landscape. Ann. Oncol. 29, 84–91.
Thorsson, V., Gibbs, D.L., Brown, S.D., Wolf, D., Bortone, D.S., Ou Yang, T.H.,
Porta-Pardo, E., Gao, G.F., Plaisier, C.L., Eddy, J.A., et al. (2018). The Immune
Landscape of Cancer. Immunity 48, 812–830.e14.
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R.A., Will, M., Li, Z., Gala, K., Fan-
ning, S., King, T.A., et al. (2013). ESR1 ligand-binding domain mutations in
hormone-resistant breast cancer. Nat. Genet. 45, 1439–1445.
Untergasser, A., Cutcutache, I., Koressaar, T., Ye, J., Faircloth, B.C., Remm,
M., and Rozen, S.G. (2012). Primer3–new capabilities and interfaces. Nucleic
Acids Res. 40, e115.
Van Loo, P., Nordgard, S.H., Lingjærde, O.C., Russnes, H.G., Rye, I.H., Sun,
W., Weigman, V.J., Marynen, P., Zetterberg, A., Naume, B., et al. (2010).
Allele-specific copy number analysis of tumors. Proc. Natl. Acad. Sci. USA
107, 16910–16915.
Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Jr.,
and Kinzler, K.W. (2013). Cancer genome landscapes. Science 339, 1546–
1558.
Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation
of genetic variants from high-throughput sequencing data. Nucleic Acids Res.
38, e164.
Wang, T., Wang, C., Wu, J., He, C., Zhang, W., Liu, J., Zhang, R., Lv, Y., Li, Y.,
Zeng, X., et al. (2017). The Different T-cell Receptor Repertoires in Breast
Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues. Cancer Immu-
nol. Res. 5, 148–156.
Watson, S.J., Welkers, M.R., Depledge, D.P., Coulter, E., Breuer, J.M., de
Jong, M.D., and Kellam, P. (2013). Viral population analysis and minority-
variant detection using short read next-generation sequencing. Philos. Trans.
R. Soc. Lond. B Biol. Sci. 368, 20120205.
Wolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Alli-
son, K.H., Allred, D.C., Bartlett, J.M., Bilous, M., Fitzgibbons, P., et al.; Amer-
ican Society of Clinical Oncology; College of American Pathologists (2013).
Recommendations for human epidermal growth factor receptor 2 testing in
breast cancer: American Society of Clinical Oncology/College of American
Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997–4013.
Yates, L.R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo,
P., Aas, T., Alexandrov, L.B., Larsimont, D., Davies, H., et al. (2015). Subclonal
diversification of primary breast cancer revealed by multiregion sequencing.
Nat. Med. 21, 751–759.
Yates, L.R., Knappskog, S., Wedge, D., Farmery, J.H.R., Gonzalez, S., Martin-
corena, I., Alexandrov, L.B., Van Loo, P., Haugland, H.K., Lilleng, P.K., et al.
(2017). Genomic Evolution of Breast Cancer Metastasis and Relapse. Cancer
Cell 32, 169–184.e167.
STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD68 Antibody Novocastra Cat# NCL-CD68; RRID: AB_563623
CD3 (Clone SP7) Thermo Scientific Cat# RM-9107-S; RRID: AB_149922
CD19 Antibody Abcam Cat# ab134114
Anti FOXP3 Antibody Abcam Cat# ab20034; RRID: AB_445284
CD8 Monoclonal Antibody Thermo Scientific Cat# RM-9116-S; RRID: AB_149960
Anti-IL3RA Atlas Cat# HPA003539; RRID: AB_1078438
Anti-IDO1 Antibody Atlas Cat# HPA027772; RRID: AB_1846222
CD4 Antibody Novocastra Cat# CD4-368-L-CE
CD56 Antibody Novocastra Cat# CD56-504-L-CE
CD1A Antibody Novocastra Cat# CD1A-235-L-CE
Mast Cell Tryptase Antibody DAKO Cat# M7052; RRID: AB_2206478
CD45RO Antibody DAKO Cat# M0742; RRID: AB_2237910
CD38 Antibody Novocastra Cat# NCL-L-CD38-290; RRID: AB_563555
PDL1 Antibody Cell Signaling
Technologies
Cat# 13684; RRID: AB_2687655
ER Novocastra Cat# NCL-ER-6F11/2; RRID: AB_876939
PR Dako Cat# M3569; RRID: AB_2532076
HER2 Abbott Diagnostics Cat# 06N46-035
Raindance Source Chips Raindance Techologies
(BioRad)
Cat# 20-04410
TaqMan Genotyping Master Mix Thermo Fisher Cat# 4371353
SPRIselect Reagent Beckman Coulter Cat# B23318
Critical Commercial Assays
DNeasy Blood and Tissue Kit QIAGEN Cat# 69506
QIAamp DNA Mini Kit QIAGEN Cat# 51306
MiRneasy mini kit QIAGEN Cat# 217004
GoTaq DNA polymerase Promega Cat# M7808
GoTaq Flexi DNA polymerase Promega Cat# M7808
SuperScript III Reverse Transcriptase ThermoFisher Scientific Cat#18080093
Illumina Nextera Rapid Capture Exome kit Illumina Cat# FC-140-1003
Quant-IT dsDNA BR Thermo Fisher Scientific Cat# Q33130
KAPA Library Quantification Kit Illumina KAPA Biosystems Cat# KK4873
DNA 1000 Kit Agilen Cat# 5067-1504
TruSeq Stranded Total RNA HT kit with
Ribo-Zero Gold
Illumina Cat# RS-122-2303
RNA 6000 Nano Kit Agilen Cat# 5067-1511
PhiX control Illumina Cat# FC-110-3001
SuperScript IV First-Strand Synthesis System ThermoFisher Scientific Cat#18091050
Deposited Data
Aligned DNA and RNA sequencing data Deposited at European Genome Archive (EGA) with
ID: EGAS00001002703
Additional supplemental figures Deposited in Mendeley Data repository.
https://doi.org/10.17632/6cv77bry6m.1
(Continued on next page)
Cell Reports 27, 2690–2708.e1–e10, May 28, 2019 e1
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Software and Algorithms
bcl2fastq2 2.17 Illumina https://support.illumina.com/sequencing/sequencing_software/
bcl2fastq-conversion-software.html
R 3.2.2 R Core Team., 2017 http://www.r-project.org
MATLAB version 9.2 1994-2017 The
MathWorks, Inc.
https://www.mathworks.com/products/matlab.html
BWA Mem v0.7.15 Li and Durbin, 2009 http://bio-bwa.sourceforge.net/




Novosort 3.02 Novocraft http://www.novocraft.com/products/novoalign/
Novoalign 3.02 Novocraft http://www.novocraft.com/products/novoalign/
MuTect Cibulskis et al., 2013 https://software.broadinstitute.org/gatk/download
Strelka 1.0.14 Saunders et al., 2012 strelka@ftp.illumina.com
VEP (The Ensembl Variant Effect Predictor) McLaren et al., 2016 http://www.ensembl.org//useast.ensembl.org/info/docs/tools/
vep/index.html?redirectsrc=//www.ensembl.org%2Finfo%2
Fdocs%2Ftools%2Fvep%2Findex.html
Integrative Genomics Viewer (IGV) Robinson et al., 2011 http://software.broadinstitute.org/software/igv/
Picard v2.2.1 Picard https://broadinstitute.github.io/picard/
samtools v1.3.1 Li et al., 2009 http://www.htslib.org/
ea-utils v1.1.2 Ea-utils https://github.com/ExpressionAnalysis/ea-utils
Bioconductor 3.2 Huber et al., 2015 http://www.bioconductor.org
Bioconductor package QDNaseq 1.2.4 Scheinin et al., 2014 http://www.bioconductor.org
GISTIC2.0 Mermel et al., 2011 https://cloud.genepattern.org/gp/landingpage/index.html
iC10: A Copy Number and Expression-Based
Classifier for Breast Tumors
Ali et al., 2014 https://rdrr.io/cran/iC10/
pam50: PAM50 classifier for identification of
breast cancer
Parker et al., 2009 https://rdrr.io/bioc/genefu/man/pam50.html
R package deconstructSigs 1.8.0 Rosenthal et al., 2016 http://www.r-project.org/
ASCAT 2.5 Van Loo et al., 2010 https://www.crick.ac.uk/peter-van-loo/software/ASCAT
PyClone 0.12.7 Roth et al., 2014 http://www.shahlab.ca
EnsDb.Hsapiens.v75 Rainer, 2016 http://bioconductor.org/packages/release/data/annotation/
html/EnsDb.Hsapiens.v75.html
POLYSOLVER Shukla et al., 2015 https://software.broadinstitute.org/cancer/cga/polysolver
pVAC-Seq pipeline Hundal et al., 2016 https://github.com/griffithlab/pVAC-Seq
Immunophenogram Charoentong et al., 2017 https://github.com/mui-icbi/Immunophenogram
MEDICC (devel branch, commit da7ed4a) Schwarz et al., 2014 https://bitbucket.org/rfs/medicc
superFreq 0.9.17 Flensburg et al., 2018 https://github.com/ChristofferFlensburg/cnv-caller
treeomics 1.7.3 Reiter et al., 2017 https://github.com/johannesreiter/treeomics
OncoNEM 1.0 Ross and Markowetz,
2016
http://bitbucket.org/edith_ross/onconem/src
Tree: Raxml v8.2.1 Stamatakis, 2014
VarScan 2.4.3 Koboldt et al., 2012 http://dkoboldt.github.io/varscan/
alleleCount 3.1.1 alleleCount https://github.com/cancerit/alleleCount
QUASR Watson et al., 2013 https://sourceforge.net/projects/quasr/
BLAST Altschul et al., 1990 ftp://ftp.ncbi.nlm.nih.gov/blast/executables/blast+/LATEST/
IMGT Lefranc, 2011 http://www.imgt.org/
Primer Design: mprimer (v1.9), primer3
(v2.3.7), in silico PCR
Koressaar and Remm,
2007; Shen et al., 2010;
Untergasser et al., 2012
N/A
(Continued on next page)
e2 Cell Reports 27, 2690–2708.e1–e10, May 28, 2019
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
ggplot2 2.2.1 ggplot2 https://ggplot2.tidyverse.org
Igraph 1.0.1 Igraph https://cran.r-project.org/web/packages/igraph/index.html
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Carlos
Caldas (Carlos.caldas@cruk.cam.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patients
Ten metastatic breast cancer patients who underwent post-mortem warm autopsies were included in this study. Nine patients were
enrolled as part of the Vall d’Hebron Institute of Oncology (VHIO) Warm Autopsy Program, and one patient was enrolled at the
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK as previously described (Murtaza et al., 2015).
Informed consent was obtained for all patients. Research autopsies were performed under VHIO Warm Autopsy Program
protocols approved by the institutional review board (IRB) of Vall d’Hebron University Hospital (Barcelona, Spain) and under a study
protocol approved by the Cambridgeshire Research Ethics Committee (Cambridgeshire 3 REC 07/Q0106/63MN.A).
METHOD DETAILS
Sample Nomenclature
Each sample identifier (ID) follows the nomenclature NNN-sample, where NNN denotes the patient ID. For whole exome sequencing
(WES) and T cell receptor (TCR) sequencing, NNN-0XX indicates sample type (solid tumor or body-fluid derived DNA) (Table S1). For
targeted amplicon sequencing and shallow whole genome sequencing (sWGS), the sample nomenclature is specified in Table S1.
Briefly, this was derived from the primary tumor (PR), metastasis (year sample was taken (i.e., 13), followed by ID)) or body-fluid
derived cell-free DNA (plasma, CSF, ascitic fluid, pleural fluid).
Nucleic acid extraction
The histologic evaluation of each diagnostic primary tumor ormetastatic lesion from autopsy of the nine VHIO patients was confirmed
on review of routine hematoxylin and eosin-stained slides. Samples were processed as previously described (De Mattos-Arruda
et al., 2015). DNA and RNA were isolated from tumor tissue using commercially available kits according to manufacturer’s specifi-
cations (Key Resources Table). DNA was extracted from peripheral blood mononuclear cells and body fluids using commercially
available kits as permanufacturer’s specifications (Key Resources Table). RNA andDNAwere quantified using the Qubit Fluorometer
(Invitrogen).
The collection, processing, DNA extraction and preparation of exome-sequencing libraries of DET52 patient for tumor tissues and
plasma samples have been described previously (Murtaza et al., 2015).
WES AND sWGS ANALYSES
DNA sequencing
Libraries for Illumina sequencing were prepared using Illumina Nextera Rapid Capture Exome kit (cat. FC-140-1003, Illumina). Prior to
library preparation DNA concentrations for each sample were quantified using a fluorescence-based method (Quant-IT dsDNA BR,
cat. Q33130, Thermo Fisher Scientific) and 50ng of genomic DNA was used for library preparation.
Samples were processed following manufacturer’s instructions (part# 15037436 Rev. J, Illumina) for WES and sWGS. Prior to first
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(cat. KK4873, KAPA Biosystems) as used as per manufacturer’s recommendations. A subset of libraries was analyzed using DNA
1000 Kit (cat. 5067-1504, Agilent).
Whole genome libraries and exome libraries were normalized and pooled in equal volumes to create balanced pools. Each pool
was normalized to a molarity of 4nM and used for sequencing with clustering concentration 20pM with 1% spike-in of PhiX control.
Sequencing was performed on an Illumina HiSeq2500 using v4 chemistry and 50 cycles single-end for s-WGS and 75 cycles paired-
end for WES.
Demultiplexing was performed using Illumina’s bcl2fastq2 v.2.17 software using default options. FASTQ files were used for sub-
sequent data analysis.
WES analyses
Adaptor and low-quality base (Phred score below 20) trimming, alignment to the GRCh37 build of the human genome, and base qual-
ity recalibration were performed using Novoalign v 3.02 (Novocraft). Coordinate sorting of reads and PCR-duplicate marking was
performed using Novosort (v 3.02). The resulting bam files for all samples for the same patient were locally realigned using the
Genome Analysis Toolkit (GATK, v 3.4.46) (DePristo et al., 2011). MuTect (version 1.1.7) was run using default parameters (Cibulskis
et al., 2013). In order to decrease the false positive rate secondary to germline variants of noisy regions within the genome, a panel of
normals derived from 300 normal tissue exomes was generated using MuTect’s artifact detection mode and supplied to MuTect
during variant calling. Strelka (version 1.0.14) (Saunders et al., 2012) was run with recommended starting parameters for BWA
and default parameters. The isSkipDepthFilters parameter was set to 1 to skip depth filtration. Only tier 1 mutations, as well as
SNVs with a QSS_NT score higher than 15 and Indels with a QSI_NT score higher than 30 were retained. Mutations present in all
samples for each patient were then concatenated into one VCF, and Haplotypecaller was used in GENOTYPE_GIVEN_ALLELES
mode to detect these mutations across all samples.
SNVs and indels that fell into any of these categories were removed:
d Rejected by MuTect for a reason different than ‘‘DBSNP Site,’’ ‘‘DBSNP Site,alt_allele_in_normal’’ or ‘‘alt_allele_in_normal.’’
Mutations rejected by MuTect by any of these reasons that were present in the 1000 Genomes Project were also rejected
d Read depth less than 10
d Variant allelic frequency less than 0.05 in all samples for one patient
d Minimum allelic frequency of 0.02 per sample
d SNVs falling in segmental duplications regions, as annotated by annovar (Wang et al., 2010) genomic superDups, were clas-
sified as potential artifacts. Those that occurred in more than one patient, or in only one patient but in less than 25% of the
samples from that patient were removed
d SNVs falling in simple repeat regions, microsatellites or homoplymers were removed.
Somatic mutations were annotated using Variant Effect Predictor (VEP, http://grch37.ensembl.org/index.html) (McLaren et al.,
2016) and visualized using IGV (Robinson et al., 2011).
sWGS analyses
50 bp single-read sWGS was performed to provide copy number profiles. FASTQ files were aligned to the GRCh37 assembly of the
human genome using BWA (Li and Durbin, 2009) and the bam files were merged, sorted and indexed using samtools (Li et al., 2009).
Duplicates were marked using Picard. Copy number profiles were obtained using the R package QDNaseq (Olshen et al., 2004),
using non-overlapping 100 kb pairs windows, and correcting for mappability and GC content.
Targeted amplicon sequencing
Targeted amplicon sequencing (TS) was performed in 464 unique amplicons derived from WES across 10 patients (average
46.4/case, range 16-127). Targeted sequencing libraries were prepared using droplet-based PCR amplification following the man-
ufacturer’s protocols for ThunderBolts Cancer Panel with specific modifications (RainDance Technologies) as previously reported
(Murtaza et al., 2015). Multiplex primers sequences are shown in Table S6. Analysis of targeted sequencing data was performed
as described previously (Murtaza et al., 2015). For each locus and non-reference allele of interest, we assessed the allele fraction
in eight control genomic DNA samples. A mutation was considered significantly detectable if minimum coverage at that locus
was 500x, and the AF in a sample was greater than or equal to 3 standard deviations higher than the mean AF in control samples,
and if present in greater than or equal to 1% allelic fraction (AF). Additionally, any samples in which over 90% of all mutations had
AFs below 5% were excluded. The mutation calls generated from targeted sequencing were then used to assess the quality of
the exome mutation calling pipeline. Any mutations detected on both WES and TS were defined as true positives (TP), mutations
detected on WES, but not TS defined as false positives (FP), mutations detected on TS but not on WES defined as false negatives
(FN), and finally mutations that were not detected on TS and WES defined as true negatives (TN). Sensitivity was subsequently
calculated as TP/(TP+FN), specificity calculated as TN/(TN+FP), precision calculated as TP/(TP+FP) and accuracy calculcated as
(TP+TN)/(TP+FP+FN+TN).
Genotyping
Germline SNPs and indels were identified in all samples using GATK HaplotypeCaller, and all tumor samples were then genotyped to
the matching normal tissues by computing the percentage of shared SNPs and indels between tumors and normal. Concordance of
more than 90% was taken to indicate related samples.e4 Cell Reports 27, 2690–2708.e1–e10, May 28, 2019
RNA-sequencing analysis
RNA sequencing
RNA sequencing libraries were prepared using the TruSeq Stranded Total RNA HT kit with Ribo-Zero Gold (cat. RS-122-2303,
Illumina). Prior to library preparation samples were quantified using a fluorescence based method and RNA quality was assessed
using RNA 6000 Nano Kit (cat. 5067-1511, Agilent) on Bioanalyzer2100 (Agilent). Depending on availability, 400-900ng of total
RNA was used for library preparation. The RNA Integrity Number (RIN) for these samples varied from 2.3 to 7.2. Samples were pro-
cessed following manufacturer’s HS (High-Sample) instruction (part# 15031048 Rev. E, Illumina). Subset of 12 libraries was analyzed
using DNA 1000 Kit (cat. 5067-1504, Agilent) and the average library length was determined as 280bp. All libraries were quantified
using qPCR. Serial dilutions were made and 100,000x dilution was used for quantification using KAPA Library Quantification Kit Illu-
mina (cat. KK4873, KAPA Biosystems). Libraries were normalized to 40nM and pooled in equal volumes to create a balanced pool.
The library pool was quantified after doing serial dilutions in triplicate and 10,000x and 100,000x dilutions were used for quantifica-
tion. The final library was normalized to 4nM and sequenced at a clustering concentration of 20pMand 22pMwith 1%spike-in of PhiX
control (cat. FC-110-3001, Illumina). Sequencing was performed on HiSeq2500 v4 chemistry single-end flow cell (Illumina) following
manufacturer’s instructions. Demultiplexing was performed using bcl2fastq2 v.2.17 software (Illumina) using default options.
RNA sequencing analyses
FASTQ files were aligned to the GRCh37 assembly of the human genome using STAR v 2.5.2b in two-pass mode for splice-aware
read alignment. Counting of reads aligned over exonic features for the purpose of differential expression was performed using the
htseq-count script in the HTSeq package (v 0.6.1) in ‘Union’ overlap resolution mode using a Gene Transfer Format (GTF) file
from Ensembl (http://www.ensembl.org//useast.ensembl.org/?redirectsrc=//www.ensembl.org%2F). The gene counts for all
samples were then collated and FPKM calculations per gene per sample performed using the rpkm() function in the edgeR
R package. De novo transcript assembly and counting of transcripts was performed using Cufflinks v2.2.1.
For variant calling, STAR-aligned BAM files were processed as per the RNA-seq GATK Best Practices. Briefly, sequencing read
duplicates were marked using Picard MarkDuplicates, followed by Split’N’Trim and mapping quality reassignment using GATK
SplitNCigarReads (v3.6). This was then followed by local realignment across indels and base quality recalibration using GATK.
Mutations detected in the corresponding DNA sequencing data were genotyped in RNA using the GENOTYPE_GIVEN_ALLELES
mode in Haplotype caller.
Selection of driver mutations
Breast cancer driver mutations were defined as those genes identified in previous publications (Lefebvre et al., 2016; Nik-Zainal et al.,
2016; Pereira et al., 2016) and non-breast cancer drivers were defined as those present at the Cancer Gene Census and non-
overlapping with breast cancer driver mutations (https://cancer.sanger.ac.uk/census/) (Table S4).
Mutational signatures
Somatic substitutions of each metastatic sample were organized into a 96-channel vector (where the six mutation classes and
their immediate flanking sequence context are taken into account), referred to hereafter as a mutational profile. Mutational signature
analysis of these mutational profiles was performed in two steps: extraction and assignment.
The first step in our analysis aimed to identify any signatures previously found in associated primary tumors that are present within
our cohort. It consisted of applying the widely adopted (Alexandrov et al., 2013) Non-negative Matrix Factorization (NNMF) algorithm
(R-CRAN package NMF - (Gaujoux and Seoighe, 2010)) to an extended dataset, where 240 additional WESmetastatic breast cancer
samples (Lefebvre et al., 2016) were added to our original 86 sample cohort. NNMF extraction was performed on these mutational
profiles, bootstrapped 100 times, and a KL-divergence error was used to assess the accuracy of each result. The rank of the NNMF
solution (i.e., the number of extracted signatures), was allowed to vary between 2-20. Across the different extractions, cosine
similarity comparison with known canonical primary tumor signatures (COSMIC) revealed the presence of Signatures 1,2,13, and
17. The use of the additional samples increased the power of the NNMF, enabling a more precise mutational profile extraction for
these four well-known breast-cancer-related signatures.
The second step consisted of assigning the contribution of the four COSMIC signatures identified (Signature 1, 2, 13, 17) to each
sample of our original 86 metastatic cohort. This was computed using a quadratic programming algorithm (R-CRAN package
limSolve - (Soetaert et al., 2009)). A minimum of either 3% of the total number of mutations of the sample or at least 10 mutations
was required for a COSMIC signature to be attributed to a sample. The assignment step was performed on four versions of themuta-
tional profiles for each patient, including: (i) all mutations, (ii) mutations shared across all samples (stem), (iii) mutations shared across
some samples (clade), and (iv) mutations uniquely present in one sample (private).
IntCluster, PAM50 and stratification into breast cancers subtypes
Matched samples (n = 60) with copy number and expression data were classified into one of the 10 Integrative Clusters using the
‘iC10’ R package (Ali et al., 2014; Curtis et al., 2012). The ‘iC10’ package uses copy number and expression from breast cancer
data, trains a pamr classifier with the features available and predicts the iC10 group. Each sample was classified into the 10 Integra-
tive Clusters and the assignment to each model was done by consensus after manual curation in specific cases. The 50-gene sub-
type predictor PAM50 was also applyied to 64 metastases with expression data using the R package genefu (Parker et al., 2009).
ASCAT
ASCAT v2.5 (Van Loo et al., 2010) was run by integrating copy number log ratios generated from QDNaseq and SNP allelic
frequencies from WES data. The gamma technology parameter was set to 1 as recommended for exome sequencing.Cell Reports 27, 2690–2708.e1–e10, May 28, 2019 e5
Phylogenetic analyses
Four multi-sample methods were used to infer the metastatic breast cancer phylogenies. MEDICC (Minimum Event Distance for
Intra-tumor Copy number Comparisons) is a method for phylogenetic reconstruction and heterogeneity quantification that uses
allele-specific copy number profiles (Schwarz et al., 2014). OncoNEM (Ross and Markowetz, 2016) and Treeomics (Reiter et al.,
2017) are tools that utilize Bayesian inference to infer phylogenetic relationships frommutation patterns of SNVs. SuperFreq is a clon-
ality tracker that uses single nucleotide variants (SNV) and copy number alterations (CNA) (Flensburg et al., 2018; Savas et al., 2016).
MEDICC
QDNaseq (Scheinin et al., 2014) was applied to the sWGS data to obtain sequencemappability and GC content adjusted log ratios of
read depth. B-allele frequencies were calculated fromWES data at previously inferred germline variant sites using alleleCounte 3.1.1.
Log ratios and B-allele frequencies were segmented on a per case basis using allele specific multi-sample segmentation (Ross et al.,
2017) and allele-specific copy number profiles were inferred using ASCAT 2.5 (Van Loo et al., 2010). The raw ASCAT copy number
profiles were compared across samples for each case and ASCAT was rerun with adjusted ploidy and/or purity estimates where
necessary to obtain the final discrete copy number profiles. Samples with copy number fits of low quality were excluded. Amaximum
copy number cut-off of ninewas applied to bothmajor andminor copy number profiles, replacing any values exceeding this threshold
to comply with MEDICC requirements. Finally, MEDICC was used to infer the phylogenies (Schwarz et al., 2014).
Treeomics
Treeomics 1.7.3 (Reiter et al., 2017) was used to infer phylogenies from both WES and targeted sequencing data. For each case,
Treeomics was used to calculate the posterior probabilities of a variant being present based on total read depth and number of reads
covering the alternative allele. To make the Treeomics analysis computationally feasible, the number of samples had to be reduced
for some of the cases. In order to keep the mutation profiles as diverse as possible and to maintain a good representation of the
different tumor populations, samples that had amutation profile similar to one of the remaining samples were excluded preferentially.
Additionally, all sites whose posterior probabilities were lower than 0.5 in all samples were removed, as these were likely to be false
positives. Finally, Treeomics was applied to each case with subclone detection switched on and all other parameters set to default.
OncoNEM
Like Treeomics, OncoNEM 1.0 (Ross and Markowetz, 2016) was used to infer phylogenies from both WES and targeted sequencing
data. Binary mutation profiles were obtained from the Treeomics posterior probability matrices by setting all entries with a mutation
probability smaller than 0.5 to 0 and to 1 otherwise. The OncoNEM analysis was performed using error parameter optimization over a
parameter range from 0.0001 to 0.1. The Bayes factor threshold epsilon was set to 2.
SuperFreq
SuperFreq was used to infer the clonal composition of the different samples fromWES data. Pileup files of theWES data were gener-
ated using samtools 1.3.1 mpileup using amaximum depth threshold of 10000, a minimummapping quality of 1 and aminimum base
quality of 15. Liberal variant calling was performed using VarScan 2.4.3 mpileu2cns with a p value filter of 0.01, no strand-bias filter
and the variant flag set to only obtain variant sites. Then SuperFreq 0.9.17 was run with default parameters using the normal of all
cases apart from DET52 as reference normal samples.
PyClone
PyClone is a Bayesian clusteringmethod that infers the clonal population structures for each sample (Murtaza et al., 2015; Roth et al.,
2014). It integrates mutation alleles, copy number calls for each sample as input to obtain cellular frequencies for each cluster in each
sample. PyClone was run using a beta- binomial density, using 40000 iterations and a burn-in sample of 20000. A minimum cluster
size of 3 was selected for WES data.
LICHeE
The previously inferred PyClone clusters were used as input for LICHeE. To remove spurious clones from the PyClone output two
filtering steps were performed. First, low prevalence clones that did not exceed a cellular prevalence of 0.1 in any of the samples
were removed. Second, if multiple clusters were present in all samples, all but the cluster with the highest cellular prevalence
were removed. To generate binary presence-absence patterns of mutation clusters across samples, a mutation set was classified
as present in a given sample if at least 40% of its mutations had a VAF larger than 0.01. Finally, LICHeE (commit 238770c) was
used to infer clone trees and sample compositions, assuming a cellular prevalence estimate error of 0.3.
Cytolytic activity score
Cytolitic activity score was calculated as the geometric mean of the GZMA and PRF1 expression levels from RNA gene expression
data (Rooney et al., 2015).
Immunophenogram and immunophenoscore calculations
The immunophenogram (Charoentong et al., 2017) was applied to determine the immunophenotypes of each tumor sample and to
enable the calculation of an aggregated score (immunophenoscore (IPS)), based on the expression of major determinants. These
factors were classified into four categories: MHC molecules (MHC), Immunomodulators (CP), Effector cells (EC), Suppressor cells
(SC), and into 20 single factors (MHC molecules, immunoinhibitors, and immunostimulators) and six cell types (effector cells: acti-
vated CD4+ T cells, activated CD8+ T cells, effector memory CD4+ T cells and effector memory CD8+ T cells; suppressive cells:
Tregs, and MDSCs).
Briefly, the algorithm generates normalized Z scores from gene expression data for a list of cancer immunity parameters (using an
input list of 162 genes (Table S5)). The outer part of thewheel illustrates sample-wise (averaged) Z scores, which is calculated for eache6 Cell Reports 27, 2690–2708.e1–e10, May 28, 2019
of the individual 26 parameters. These Z scores are positively weighted according to stimulatory factors (cell types) and negatively
weighted according to inhibitory factors (cell types) and averaged. The inner wheel illustrates the weighted Z scores of the factors
included into the four categories. Z scores R 3 were designated as IPS10 and z-scores % 0 are designated as IPS0.
Unsupervised hierarchical clustering based on the Euclidean distance matrix of the Z scores across metastases (R heatmap.3
function) were used to produce the heatmaps.
HLA typing and in silico neoantigen prediction pipeline
For the metastases of all patients, the 4-digit HLA type was determined using POLYSOLVER (POLYmorphic loci reSOLVER) as
previously described (Shukla et al., 2015).
The pVAC-Seq pipeline (Hundal et al., 2016) was used with minor modifications. All nonsynonymous point mutations identified
were translated into strings of 17-21 amino acids with the mutant amino acid situated centrally. A sliding window method was
used to identify amino acid substrings within the mutant 17-mer that had a predicted MHC Class I binding affinity of % 500nM to
one (or more) of the patient-specific HLA alleles. Binding affinity for the mutant and corresponding wild-type nonamer were analyzed
using the NetMHCPan v3 prediction tool bundled within the IEDB MHC-I binding prediction resources. Following this, for all cases
excluding DET52 (which did not have any RNA expression data), candidate neoantigens were further filtered by retaining mutations
that were also present in the RNA sequencing data, as well as had a gene and transcript RPKM expression of more than 1. Neoanti-
genswere subsequently classified as stem, private and clade by applying the classification derived from theWESmutational dataset.
When generating Figure 5A, highly similar neoantigens generated from one mutation were counted as one.
Neo-antigen simulations
Simulations procedure
We assumed that each gene has its own mutation rate. For each gene, we used the mutations list of 4,742 WES tumor normal pairs
from (Lawrence et al., 2014) (http://www.tumorportal.org) to estimate the gene relative background mutation rate by counting the
amount of mutations the gene had divided by the total number of mutations. Every mutation was then randomly assigned to a
new gene based on the gene’s relative rate. The position within the gene was chosen to maintain the trinucleotide context of
each mutation (the 50 and 30 nearest neighbors and the mutated position) and the variant was based on the original mutation. In addi-
tion, for every base we counted how many times it was sufficiently covered for mutation detection (i.e., > = 14 reads), across 7,732
TCGA tumor WES samples. The fraction of covered patients at a given base was used as a probabilistic weight when selecting the
new position for a mutation.
P value calculation
For a single sample analysis we defined the P-value as the fraction of replications (out 100) that had a neo-epitopes ratio larger than 1.
For combining cases based on their target tissue we tried to see if their average was less expected at random. For that we generated
20 replicates and and 100 additional simulations based on each of the 20 replicates. We then calculated the average neo-epitopes
ratio for each of these sets and compared it to the original ratio. We then calculated a P value for the fraction of the real average being
different from the simulations average.
Loss of heterozygosity in human leukocyte antigen (LOHHLA)
LOH over the HLA Class I locus was identified using LOHHLA on the whole exome sequencing data, and LOH called if the copy
number at HLA-A/HLA-B or HLA-C locus was less than 0.5, with a p value of less than 0.05 (McGranahan et al., 2017).
T cell receptor (TCR) analysis
TCR-sequencing library preparation
Reverse transcription primers were designed using Primer3 (Koressaar and Remm, 2007; Untergasser et al., 2012) and multiplex
PCR primers using MPrimer (Shen et al., 2010). cDNA synthesis was performed using TCR-a or TCR-b constant region-specific
primers carrying amolecular barcode of 12 random/degenerate nucleotides (N12, TNNNNTNNNNTNNNNT) to enablemolecule-level
identification (unique molecular identifier). The molecular barcode was inserted upstream (50) of the sequence that recognizes the
constant region(s) and downstream (30) of an adaptor sequence complementary to first round PCR reverse primers.
Reverse transcription was performed with SuperScript IV First-Strand Synthesis System (Invitrogen, ThermoFisher Scientific)
using 500ng to 2 mg of total RNA, 1 mL of barcoded TCR-a or TCR-b specific reverse primer (0.1 mM final), 1 mL of dNTPs (0.5mM
final) and added with nuclease-free water to a total volume of 13 ml. This was incubated at 65C for 5min, then on ice for 2 minutes
and followed by addition of 4 mL of 5X First strand buffer, 1 mL of DTT (5mM final), 1 mL of RNaseOUT Recombinant Ribonuclease
Inhibitor (40 units), and 1 mL of SuperScript IV reverse transcriptase (200 units). The reactionwas incubated at 56C for 60min followed
by inactivation at 80C for 10min. 1 mL of E. coliRNaseH (2 units) was added and incubated at 37C for 20min to remove RNA from the
cDNA:RNA hybrids. The first strand cDNA was cleaned up using 1.8x Agencourt Ampure XP beads (Beckman Coulter) and eluted
with 21 mL of nuclease-free water (Ambion).
First-roundmultiplex PCR amplifications were set up in a total volume of 50 ml, with 20 mL of cDNA as template, 25 mL of Q5Hotstart
High-Fidelity DNA Polymerase Master Mix 2x (New England Biolabs) and tailed TCR-a or TCR-b forward primer set pools and sam-
ple-indexed reverse primers (0.2uM final concentration each). Multiplex forward primers target different TCR-a or TCR-b V-regions
and sequences are shown in Table S7. The sample-indexed reverse primers used were published previously (Bronner et al., 2014).
The following PCR programwas used: 30 s at 98C, 25 cycles of 20 s at 98C, 1 min at 55C, and 1min at 72C, with a final extensionCell Reports 27, 2690–2708.e1–e10, May 28, 2019 e7
step of 2 min at 72C. The PCR product was cleaned up using 0.75x Agencourt Ampure XP beads (Beckman Coulter) and eluted with
20 mL of nuclease-free water (Ambion).
First-round forward (TCR-a or TCR-b V-region-specific) PCR primers each contained a shared sequence to allow Illumina
sequencing adapters to be introduced with a second round PCR. The second-round PCR amplification step was performed on
the first round PCR amplicons to generate Illumina-ready sequencing libraries. 12 cycles of PCRs were performed and the product
was analyzed and quantitated using Agilent Bioanalyzer DNA 1000 chips. For each batch, equal nanomoles of each sample were
pooled, double SPRI size selected (0.5x and 0.7x) and stored at 20C until sequencing. Libraries were batched and sequenced
on MiSeq sequencers (300bp paired-end reads).
TCR-sequencing and barcode filtering
MiSeq libraries were prepared using Illumina protocols and sequenced using 300bp paired-endedMiSeq (Illumina). RawMiSeq reads
were filtered for base quality (median Phred score > 32) using the QUASR program (https://sourceforge.net/projects/quasr/) (Watson
et al., 2013).MiSeq forward and reverse readsweremerged together if they contained identical overlapping region of > 50bp, or other-
wise discarded. Universal barcoded regions were identified in reads and orientated to read from V-primer to constant region primer.
The barcoded region within each primer was identified and checked for conserved bases (i.e., the T’s in NNNNTNNNNTNNNNT).
Primers and constant regions were trimmed from each sequence, and sequences were retained only if there was > 80% sequence
certainty between all sequences obtained with the same barcode, otherwise discarded. The constant region allele with highest
sequence similarity was identified by k-mermatching (where k = 10bp) to the reference constant region gene IMGT database (Lefranc,
2011), and sequence trimmed to give only the region of the sequence corresponding to the variable (V-D-J) regions, where constant
region usage information for each TCR was retained throughout the analysis. Sequences without complete reading frames and
non-TCR sequences were removed and only reads with significant similarity to reference TRBV or TRAV and J genes from the
IMGT database were retained using BLAST (Altschul et al., 1990). Sequences were annotated using IMGT. Sample clustering was
performed as previously described (Bashford-Rogers et al., 2013).
TCR repertoire generation and network analysis
The network generation algorithm and network properties were calculated as in Bashford-Rogers et al.(Bashford-Rogers et al.,
2013): each vertex represents a unique sequence, where relative vertex size is proportional to the number of identical reads. A clone
(cluster) refers to a group of identical related T cells, each containing TCRs with identical CDR3 regions and TCRV gene usage.
Repertoire parameters that were dependent on sequencing depth were generated by subsampling each sequencing sample to a
specified depth and the mean of 20 repeats of resulting parameters were calculated using the clonality measures. These measures
include 1) total repertoire clonality (vertex & cluster Gini Indices), and 2) mean cluster sizes, (3) largest cluster sizes calculated as
follows:
1) Total repertoire clonality, measured by vertex & cluster Gini Indices are defined in Bashford-Rogers et al. (Bashford-Rogers
et al., 2013), calculated from the distribution of the number of unique RNA molecules per vertex and the distribution of the
number of unique TCRs per cluster, respectively. These were all calculated per 1000 read subsample of the each total TCR
repertoire.
2) Mean cluster sizes (MCS) were within each subsample for the total TCR repertoire were calculated as follows for any given
sample Y:MCSðSample YÞ=
P
N TCRs per cluster in subsample
P
Total number of clusters in subsample
x100
3) Largest cluster sizes (LCS) were within each subsample for the total TCR repertoire were calculated as follows for any given
sample Y:MCSðSample YÞ= MaxðN TCRs per cluster in subsampleÞP
Total number of clusters in subsample
x100Clonal overlap analysisClonal groups defined as TCRs sharing same V and J gene usages and identical CDR3 region sequence (nucleotide). Public TCRs
were defined as TCR clusters that were shared between 2 or more T cell samples from unrelated individuals within this dataset and
compared to the Adaptive Biotechnology database (Dean et al., 2015). The clonal overlap coefficient, describing the overlap between
samples, was calculated either considering the whole TCR datasets, or with the public TCR clones removed.
Clonal overlap, Oði; jÞ; between any two samples, i and j was calculated by
Oði; jÞ= Ci;j
1 =2 ðCi +CjÞ
Where Cx is the number of clusters in sample x and Ci;j is the number of clusters shared between samples i and j. To account for
differences in sequencing depth between samples, each sample was subsampled each sequencing sample to a specified depth
(1000 TCRs), and the mean of 20 repeats per sample of resulting clonal overlap was calculated.e8 Cell Reports 27, 2690–2708.e1–e10, May 28, 2019
Similarity heatmaps
Similarity heatmaps were produced using Jaccard index calculated between each pair of metastases, using unique amino acids
TCRs (CDR3s), for the alpha and beta chains. The Jaccard index was calculated using the ecological toolkit of the vegan R package,
and the heatmaps were produced using R pheatmap package. Clustering of the heatmaps was done by the standard R hclust
(hierarchical clustering) method, using the ‘‘complete’’ option. The comparison of the hclusts objects was done by the cophenetic
correlation, using the dendextend package (Galili, 2015).
The data were reshuffled to assign the TCR sequences to ‘‘randomized’’ metastases, and then on the reshuffled repertoire clus-
tering by the Jaccard index was performed. This randomization was done 100 times. In this setting where there are 100 clusterings
performed on the different randomizations and these were compared then between themselves, and to the original clustering of the
biological data. To compare the randomized and ‘real’ trees we used the cophenetic correlation, and the Robinson-Foulds metric.
The comparison of the Jaccard clustering trees with the genetic trees was done by using the cophenetic definition for edge-
weighted trees. In this version of the cophenetic, the distance between each pair of nodes is the sum of the edges weights along
the path connecting these pair of nodes.
Correlation of TPM of CDR3 genes and sum of TCR reads
From the RNASeqwe extracted the TPM values of four genes that encode for the four different parts of the CD3 complex. These genes
are CD3D, CD3G, CD3E and the zeta chain CD247 (Ensembl codes: ENSG00000167286, ENSG00000160654, ENSG00000198851,
ENSG00000198821, respectively). For each sample, we calculated twomeasurements: 1) the sumof theRNASeqTPMvalues for these
four genes; 2) from the TCR repertoires - the sum of the number of alpha chains and beta chains for each sample. We computed the
Pearson correlation between the log10 values of these two measurements across all samples. The correlation and p value were
computed using R’s cor.test method.
Histopathological analyses
Tissue microarrays (TMA) were prepared using duplicate 1 mm cores extracted from formalin-fixed paraffin-embedded blocks con-
taining material from the individual tumors and metastases.
Immunohistochemistry (IHC) was conducted for CD68, CD3, CD19, FOXP3, CD8, IL3RA, IDO1, CD4, CD56, CD1A, Mast Cell
Tryptase, CD45RO, CD38, PDL1, ER, PR, and HER2 proteins. Details of reagents and protocols for IHC are provided in Key
Resources Table.
Stains weremanually quantified by counting the absolute number or the percentage of positive stained cells. ER, PR statuses were
assessed based on IHC applied to TMAs and scored using the percentage of positive tumor cells and intensity of staining (AllRead
score). Herceptest was performed for all samples according to ASCO/CAP Guidelines (Wolff et al., 2013).
Fluorescence in situ hybridization (FISH) (HER2-to-CEP17 ratio and gene copy number) for HER2 status was performed as
previously described for all samples (Wolff et al., 2013). Positive HER2 amplification was considered when FISH ratio was higher
than 2.2 or HER2 gene copy greater than 6.0.
Digital pathology
Whole slide images (either FFPE sections or frozen sections from tissue samples used for RNA extraction) were analyzed using
CellExtractor v1.0, an open-source platform developed for high throughput analysis of histopathological images. The code was writ-
ten in Python and used the OpenCV, i.e., an open source computer vision and machine learning software library written in C++, and
the OpenSlide library. Full-face H&E scanned images were analyzed and divided into several sub-regions. Each sub-region is pro-
cessed and segmented to compute cellular features such as centroids, shape descriptors, and pixel intensities. These features were
used to train a support-vector machine (SVM) based classifier to identify cancer cells, stromal cells, and lymphocytes based on a
training set of objects selected by a pathologist (W.C.) of approximately 1,000 objects for each category. Finally, based on these clas-
ses descriptive statistical parameters such as cellular fractions and densities were estimated. For each detected cell density was
obtained based on counting the number of nearest neighbor approach, i.e., the density within the distance to the Nth nearest
neighbor calculated as follow: Sigma_N (pixel̂ [-2]) = N/(pi* d_N̂ 2), Where d_N is the distance to the Nth nearest neighbor within a
density-defining population. A value of N = 50was used in order to estimate the density parameter (see (Ali et al., 2016b) for a detailed
description).
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed using R version 3.2.2 and associated packages (Key Resources Table). The statistical details
of experiments including the exact value of n in terms of number of samples for a given patient, the experimental method and specific
statistical tests employed are reported in the relevant section, Results, Figures and Figure Legends, and Supplementary tables. For a
given test (i.e., Wilcoxon rank sum, test chi-square test) significance was defined if a p value was less than 0.05.
DATA AND SOFTWARE AVAILABILITY
Software
Customscripts to run the analysesdescribed in themanuscript are available at https://github.com/cclab-brca/MET-breast-landscapes/Cell Reports 27, 2690–2708.e1–e10, May 28, 2019 e9
Data Resources
Sequence data has been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG,
under accession number EGAS00001002703. Further information about EGA can be found on https://ega-archive.org. The
European Genome-phenome Archive of human data consented for biomedical research (https://idp.nature.com/authorize?
response_type=cookie&client_id=grover&redirect_uri=http%3A%2F%2Fwww.nature.com%2Fng%2Fjournal%2Fv47%2Fn7%2F
full%2Fng.3312.html). Supplemental Information was deposited on Mendeley at https://doi.org/10.17632/6cv77bry6m.1e10 Cell Reports 27, 2690–2708.e1–e10, May 28, 2019
